AU2007271743B2 - Substituted 4-aryl-chromene as activator of caspases and inducer of apoptosis and as antivascular agent and the use thereof - Google Patents
Substituted 4-aryl-chromene as activator of caspases and inducer of apoptosis and as antivascular agent and the use thereof Download PDFInfo
- Publication number
- AU2007271743B2 AU2007271743B2 AU2007271743A AU2007271743A AU2007271743B2 AU 2007271743 B2 AU2007271743 B2 AU 2007271743B2 AU 2007271743 A AU2007271743 A AU 2007271743A AU 2007271743 A AU2007271743 A AU 2007271743A AU 2007271743 B2 AU2007271743 B2 AU 2007271743B2
- Authority
- AU
- Australia
- Prior art keywords
- compound
- cancer
- carcinoma
- stereoisomer
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 239000004066 vascular targeting agent Substances 0.000 title claims abstract description 31
- 230000006907 apoptotic process Effects 0.000 title abstract description 62
- 108010076667 Caspases Proteins 0.000 title abstract description 47
- 102000011727 Caspases Human genes 0.000 title abstract description 47
- 239000000411 inducer Substances 0.000 title abstract description 31
- 239000012190 activator Substances 0.000 title abstract description 30
- 150000001875 compounds Chemical class 0.000 claims abstract description 163
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 72
- 238000011282 treatment Methods 0.000 claims abstract description 30
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 29
- 210000005166 vasculature Anatomy 0.000 claims abstract description 17
- 201000010099 disease Diseases 0.000 claims abstract description 16
- 206010029113 Neovascularisation Diseases 0.000 claims abstract description 6
- 208000012868 Overgrowth Diseases 0.000 claims abstract description 5
- -1 hydroxy, carboxy, carbamoyl Chemical group 0.000 claims description 73
- 210000004027 cell Anatomy 0.000 claims description 67
- 125000000217 alkyl group Chemical group 0.000 claims description 48
- 238000000034 method Methods 0.000 claims description 42
- 229940002612 prodrug Drugs 0.000 claims description 41
- 239000000651 prodrug Substances 0.000 claims description 41
- 150000003839 salts Chemical class 0.000 claims description 35
- 125000003118 aryl group Chemical group 0.000 claims description 32
- 229910052739 hydrogen Inorganic materials 0.000 claims description 30
- 201000011510 cancer Diseases 0.000 claims description 29
- 239000002246 antineoplastic agent Substances 0.000 claims description 27
- 241001465754 Metazoa Species 0.000 claims description 25
- 239000001257 hydrogen Substances 0.000 claims description 24
- 239000008194 pharmaceutical composition Substances 0.000 claims description 22
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 21
- 229920001223 polyethylene glycol Polymers 0.000 claims description 19
- 229940024606 amino acid Drugs 0.000 claims description 17
- 235000001014 amino acid Nutrition 0.000 claims description 17
- 150000001413 amino acids Chemical class 0.000 claims description 17
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 16
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 14
- 208000035475 disorder Diseases 0.000 claims description 13
- 239000003814 drug Substances 0.000 claims description 12
- 239000011780 sodium chloride Substances 0.000 claims description 12
- 239000003795 chemical substances by application Substances 0.000 claims description 11
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 11
- 229960004316 cisplatin Drugs 0.000 claims description 11
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 claims description 10
- 229960004679 doxorubicin Drugs 0.000 claims description 10
- 229940079593 drug Drugs 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- 210000001519 tissue Anatomy 0.000 claims description 9
- 201000009030 Carcinoma Diseases 0.000 claims description 8
- 241000124008 Mammalia Species 0.000 claims description 8
- 206010006187 Breast cancer Diseases 0.000 claims description 7
- 208000026310 Breast neoplasm Diseases 0.000 claims description 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 7
- 239000012830 cancer therapeutic Substances 0.000 claims description 7
- 239000008121 dextrose Substances 0.000 claims description 7
- 210000002889 endothelial cell Anatomy 0.000 claims description 7
- 230000002401 inhibitory effect Effects 0.000 claims description 7
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 7
- 229940124597 therapeutic agent Drugs 0.000 claims description 7
- 206010009944 Colon cancer Diseases 0.000 claims description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 6
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 6
- 229910052799 carbon Inorganic materials 0.000 claims description 6
- 230000003211 malignant effect Effects 0.000 claims description 6
- 229960000485 methotrexate Drugs 0.000 claims description 6
- 206010060862 Prostate cancer Diseases 0.000 claims description 5
- 229920001400 block copolymer Polymers 0.000 claims description 5
- 229960001338 colchicine Drugs 0.000 claims description 5
- 238000009833 condensation Methods 0.000 claims description 5
- 230000005494 condensation Effects 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 5
- 230000012010 growth Effects 0.000 claims description 5
- 229920001451 polypropylene glycol Polymers 0.000 claims description 5
- 229920000136 polysorbate Polymers 0.000 claims description 5
- 238000001959 radiotherapy Methods 0.000 claims description 5
- 208000016691 refractory malignant neoplasm Diseases 0.000 claims description 5
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical group NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 claims description 4
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 4
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 claims description 4
- 206010029260 Neuroblastoma Diseases 0.000 claims description 4
- 206010033128 Ovarian cancer Diseases 0.000 claims description 4
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 4
- 229960003767 alanine Drugs 0.000 claims description 4
- 125000003277 amino group Chemical group 0.000 claims description 4
- 229940022353 herceptin Drugs 0.000 claims description 4
- 206010020718 hyperplasia Diseases 0.000 claims description 4
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 4
- 229950008882 polysorbate Drugs 0.000 claims description 4
- 229920000053 polysorbate 80 Polymers 0.000 claims description 4
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims description 3
- 239000004471 Glycine Substances 0.000 claims description 3
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 3
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 3
- 229930012538 Paclitaxel Natural products 0.000 claims description 3
- 239000002202 Polyethylene glycol Substances 0.000 claims description 3
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 3
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 3
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 claims description 3
- 235000004279 alanine Nutrition 0.000 claims description 3
- 150000001299 aldehydes Chemical class 0.000 claims description 3
- 150000001408 amides Chemical class 0.000 claims description 3
- 125000004432 carbon atom Chemical group C* 0.000 claims description 3
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims description 3
- 229960002449 glycine Drugs 0.000 claims description 3
- 201000001441 melanoma Diseases 0.000 claims description 3
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 3
- 229960001592 paclitaxel Drugs 0.000 claims description 3
- 229960002429 proline Drugs 0.000 claims description 3
- 201000000849 skin cancer Diseases 0.000 claims description 3
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 3
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 3
- 229960003048 vinblastine Drugs 0.000 claims description 3
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 claims description 3
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims description 3
- 229960004528 vincristine Drugs 0.000 claims description 3
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims description 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 2
- DEQANNDTNATYII-OULOTJBUSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-n-[(2r,3r)-1,3-dihydroxybutan-2-yl]-7-[(1r)-1-hydroxyethyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxa Chemical compound C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)C1=CC=CC=C1 DEQANNDTNATYII-OULOTJBUSA-N 0.000 claims description 2
- ZGNLFUXWZJGETL-YUSKDDKASA-N (Z)-[(2S)-2-amino-2-carboxyethyl]-hydroxyimino-oxidoazanium Chemical compound N[C@@H](C\[N+]([O-])=N\O)C(O)=O ZGNLFUXWZJGETL-YUSKDDKASA-N 0.000 claims description 2
- VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 claims description 2
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 claims description 2
- NMUSYJAQQFHJEW-UHFFFAOYSA-N 5-Azacytidine Natural products O=C1N=C(N)N=CN1C1C(O)C(O)C(CO)O1 NMUSYJAQQFHJEW-UHFFFAOYSA-N 0.000 claims description 2
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 claims description 2
- WYWHKKSPHMUBEB-UHFFFAOYSA-N 6-Mercaptoguanine Natural products N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 claims description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 2
- 239000004475 Arginine Substances 0.000 claims description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims description 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 2
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 claims description 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 2
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 108010006654 Bleomycin Proteins 0.000 claims description 2
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 claims description 2
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 claims description 2
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims description 2
- 208000017897 Carcinoma of esophagus Diseases 0.000 claims description 2
- 208000006332 Choriocarcinoma Diseases 0.000 claims description 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 2
- 206010014733 Endometrial cancer Diseases 0.000 claims description 2
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 2
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 claims description 2
- 208000032027 Essential Thrombocythemia Diseases 0.000 claims description 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 2
- 208000017604 Hodgkin disease Diseases 0.000 claims description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 2
- 208000037147 Hypercalcaemia Diseases 0.000 claims description 2
- 208000007766 Kaposi sarcoma Diseases 0.000 claims description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 2
- MLFKVJCWGUZWNV-UHFFFAOYSA-N L-alanosine Natural products OC(=O)C(N)CN(O)N=O MLFKVJCWGUZWNV-UHFFFAOYSA-N 0.000 claims description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 2
- 239000002147 L01XE04 - Sunitinib Substances 0.000 claims description 2
- 239000005511 L01XE05 - Sorafenib Substances 0.000 claims description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 2
- 239000004472 Lysine Substances 0.000 claims description 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims description 2
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 2
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Chemical group CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 claims description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 2
- 108010016076 Octreotide Proteins 0.000 claims description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 229920000604 Polyethylene Glycol 200 Polymers 0.000 claims description 2
- 229920001213 Polysorbate 20 Polymers 0.000 claims description 2
- 206010039491 Sarcoma Diseases 0.000 claims description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 2
- 208000021712 Soft tissue sarcoma Diseases 0.000 claims description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 2
- 239000004473 Threonine Substances 0.000 claims description 2
- 208000033781 Thyroid carcinoma Diseases 0.000 claims description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 2
- 208000008383 Wilms tumor Diseases 0.000 claims description 2
- USZYSDMBJDPRIF-SVEJIMAYSA-N aclacinomycin A Chemical compound O([C@H]1[C@@H](O)C[C@@H](O[C@H]1C)O[C@H]1[C@H](C[C@@H](O[C@H]1C)O[C@H]1C[C@]([C@@H](C2=CC=3C(=O)C4=CC=CC(O)=C4C(=O)C=3C(O)=C21)C(=O)OC)(O)CC)N(C)C)[C@H]1CCC(=O)[C@H](C)O1 USZYSDMBJDPRIF-SVEJIMAYSA-N 0.000 claims description 2
- 229960004176 aclarubicin Drugs 0.000 claims description 2
- 208000017733 acquired polycythemia vera Diseases 0.000 claims description 2
- 230000001154 acute effect Effects 0.000 claims description 2
- 208000020990 adrenal cortex carcinoma Diseases 0.000 claims description 2
- 229950005033 alanosine Drugs 0.000 claims description 2
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 claims description 2
- 150000008064 anhydrides Chemical class 0.000 claims description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 2
- 229960003121 arginine Drugs 0.000 claims description 2
- 235000009697 arginine Nutrition 0.000 claims description 2
- 229960001230 asparagine Drugs 0.000 claims description 2
- 235000009582 asparagine Nutrition 0.000 claims description 2
- 229960005261 aspartic acid Drugs 0.000 claims description 2
- 235000003704 aspartic acid Nutrition 0.000 claims description 2
- 229960002756 azacitidine Drugs 0.000 claims description 2
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 claims description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 2
- 201000001531 bladder carcinoma Diseases 0.000 claims description 2
- 229960001561 bleomycin Drugs 0.000 claims description 2
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 claims description 2
- 210000004556 brain Anatomy 0.000 claims description 2
- 201000008275 breast carcinoma Diseases 0.000 claims description 2
- 229960002092 busulfan Drugs 0.000 claims description 2
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 claims description 2
- 229940127093 camptothecin Drugs 0.000 claims description 2
- 229960004562 carboplatin Drugs 0.000 claims description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 2
- 208000002458 carcinoid tumor Diseases 0.000 claims description 2
- 208000019065 cervical carcinoma Diseases 0.000 claims description 2
- 229960004630 chlorambucil Drugs 0.000 claims description 2
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 claims description 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims description 2
- 229960002433 cysteine Drugs 0.000 claims description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 2
- 235000018417 cysteine Nutrition 0.000 claims description 2
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Chemical group CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 claims description 2
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 claims description 2
- 229960003668 docetaxel Drugs 0.000 claims description 2
- YZQRAQOSAPWELU-UHFFFAOYSA-O elliptinium Chemical compound C[N+]1=CC=C2C(C)=C(NC=3C4=CC(O)=CC=3)C4=C(C)C2=C1 YZQRAQOSAPWELU-UHFFFAOYSA-O 0.000 claims description 2
- 229950007539 elliptinium Drugs 0.000 claims description 2
- 201000003914 endometrial carcinoma Diseases 0.000 claims description 2
- 229960001904 epirubicin Drugs 0.000 claims description 2
- 201000005619 esophageal carcinoma Diseases 0.000 claims description 2
- 229960005420 etoposide Drugs 0.000 claims description 2
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims description 2
- 208000021045 exocrine pancreatic carcinoma Diseases 0.000 claims description 2
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 claims description 2
- 229960000390 fludarabine Drugs 0.000 claims description 2
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 claims description 2
- 229960002949 fluorouracil Drugs 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 208000010749 gastric carcinoma Diseases 0.000 claims description 2
- 229960002989 glutamic acid Drugs 0.000 claims description 2
- 235000013922 glutamic acid Nutrition 0.000 claims description 2
- 239000004220 glutamic acid Substances 0.000 claims description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 2
- 235000004554 glutamine Nutrition 0.000 claims description 2
- 229960002743 glutamine Drugs 0.000 claims description 2
- 201000009277 hairy cell leukemia Diseases 0.000 claims description 2
- 201000003911 head and neck carcinoma Diseases 0.000 claims description 2
- 229960002885 histidine Drugs 0.000 claims description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 2
- 230000000148 hypercalcaemia Effects 0.000 claims description 2
- 208000030915 hypercalcemia disease Diseases 0.000 claims description 2
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 claims description 2
- 229960001101 ifosfamide Drugs 0.000 claims description 2
- 150000002466 imines Chemical class 0.000 claims description 2
- 229960000310 isoleucine Drugs 0.000 claims description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 2
- 150000002576 ketones Chemical class 0.000 claims description 2
- 229960003136 leucine Drugs 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims description 2
- 208000014018 liver neoplasm Diseases 0.000 claims description 2
- 201000005296 lung carcinoma Diseases 0.000 claims description 2
- 229960003646 lysine Drugs 0.000 claims description 2
- 229960001924 melphalan Drugs 0.000 claims description 2
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 claims description 2
- 229930182817 methionine Natural products 0.000 claims description 2
- 229960004452 methionine Drugs 0.000 claims description 2
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 claims description 2
- MXWHMTNPTTVWDM-NXOFHUPFSA-N mitoguazone Chemical compound NC(N)=N\N=C(/C)\C=N\N=C(N)N MXWHMTNPTTVWDM-NXOFHUPFSA-N 0.000 claims description 2
- 229960003539 mitoguazone Drugs 0.000 claims description 2
- 229960004857 mitomycin Drugs 0.000 claims description 2
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 claims description 2
- 229960001156 mitoxantrone Drugs 0.000 claims description 2
- 201000005962 mycosis fungoides Diseases 0.000 claims description 2
- 229960002700 octreotide Drugs 0.000 claims description 2
- 201000008968 osteosarcoma Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 208000021255 pancreatic insulinoma Diseases 0.000 claims description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 2
- 229960005190 phenylalanine Drugs 0.000 claims description 2
- 208000037244 polycythemia vera Diseases 0.000 claims description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 2
- 229940068977 polysorbate 20 Drugs 0.000 claims description 2
- 229940068968 polysorbate 80 Drugs 0.000 claims description 2
- 208000015347 renal cell adenocarcinoma Diseases 0.000 claims description 2
- 229930002330 retinoic acid Natural products 0.000 claims description 2
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims description 2
- 229960005399 satraplatin Drugs 0.000 claims description 2
- 190014017285 satraplatin Chemical group 0.000 claims description 2
- 229960001153 serine Drugs 0.000 claims description 2
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 2
- 229960003787 sorafenib Drugs 0.000 claims description 2
- 201000000498 stomach carcinoma Diseases 0.000 claims description 2
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 claims description 2
- 229960001796 sunitinib Drugs 0.000 claims description 2
- 238000001356 surgical procedure Methods 0.000 claims description 2
- 230000002381 testicular Effects 0.000 claims description 2
- 229960002898 threonine Drugs 0.000 claims description 2
- 201000002510 thyroid cancer Diseases 0.000 claims description 2
- 208000013077 thyroid gland carcinoma Diseases 0.000 claims description 2
- 229960003087 tioguanine Drugs 0.000 claims description 2
- MNRILEROXIRVNJ-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=NC=N[C]21 MNRILEROXIRVNJ-UHFFFAOYSA-N 0.000 claims description 2
- 229960000303 topotecan Drugs 0.000 claims description 2
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 claims description 2
- 229960001727 tretinoin Drugs 0.000 claims description 2
- 229960004799 tryptophan Drugs 0.000 claims description 2
- 229960004441 tyrosine Drugs 0.000 claims description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 2
- 208000010570 urinary bladder carcinoma Diseases 0.000 claims description 2
- 229960004295 valine Drugs 0.000 claims description 2
- 239000004474 valine Substances 0.000 claims description 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 230000030833 cell death Effects 0.000 abstract description 12
- 230000002159 abnormal effect Effects 0.000 abstract description 6
- 230000004222 uncontrolled growth Effects 0.000 abstract description 2
- 125000001819 4H-chromenyl group Chemical class O1C(=CCC2=CC=CC=C12)* 0.000 abstract 1
- JXONINOYTKKXQQ-CQSZACIVSA-N Crolibulin Chemical compound BrC1=C(OC)C(OC)=CC([C@@H]2C3=CC=C(N)C(N)=C3OC(N)=C2C#N)=C1 JXONINOYTKKXQQ-CQSZACIVSA-N 0.000 description 37
- 239000000203 mixture Substances 0.000 description 35
- 125000000623 heterocyclic group Chemical group 0.000 description 32
- 239000000243 solution Substances 0.000 description 29
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 27
- 125000001072 heteroaryl group Chemical group 0.000 description 22
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 18
- 125000002837 carbocyclic group Chemical group 0.000 description 18
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 14
- 230000006870 function Effects 0.000 description 14
- 239000002904 solvent Substances 0.000 description 14
- JXONINOYTKKXQQ-UHFFFAOYSA-N 2,7,8-triamino-4-(3-bromo-4,5-dimethoxyphenyl)-4h-chromene-3-carbonitrile Chemical compound BrC1=C(OC)C(OC)=CC(C2C3=CC=C(N)C(N)=C3OC(N)=C2C#N)=C1 JXONINOYTKKXQQ-UHFFFAOYSA-N 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 13
- 125000003710 aryl alkyl group Chemical group 0.000 description 13
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 12
- 239000000725 suspension Substances 0.000 description 12
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 11
- 125000004446 heteroarylalkyl group Chemical group 0.000 description 11
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 10
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 10
- 230000015572 biosynthetic process Effects 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 10
- 230000005526 G1 to G0 transition Effects 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 210000001744 T-lymphocyte Anatomy 0.000 description 9
- 230000004913 activation Effects 0.000 description 9
- 125000003545 alkoxy group Chemical group 0.000 description 9
- 125000004103 aminoalkyl group Chemical group 0.000 description 9
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 9
- 239000003153 chemical reaction reagent Substances 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 125000001188 haloalkyl group Chemical group 0.000 description 9
- 150000002431 hydrogen Chemical class 0.000 description 9
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 9
- 238000002347 injection Methods 0.000 description 9
- 239000007924 injection Substances 0.000 description 9
- 239000007787 solid Substances 0.000 description 9
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 8
- 208000023275 Autoimmune disease Diseases 0.000 description 8
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 8
- 125000003342 alkenyl group Chemical group 0.000 description 8
- 125000000304 alkynyl group Chemical group 0.000 description 8
- 125000005018 aryl alkenyl group Chemical group 0.000 description 8
- 125000005015 aryl alkynyl group Chemical group 0.000 description 8
- 125000004185 ester group Chemical group 0.000 description 8
- 125000004447 heteroarylalkenyl group Chemical group 0.000 description 8
- 125000005312 heteroarylalkynyl group Chemical group 0.000 description 8
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 8
- 239000003112 inhibitor Substances 0.000 description 8
- 229920001983 poloxamer Polymers 0.000 description 8
- 238000000926 separation method Methods 0.000 description 8
- 230000004663 cell proliferation Effects 0.000 description 7
- 125000001475 halogen functional group Chemical group 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 230000004083 survival effect Effects 0.000 description 7
- 210000002437 synoviocyte Anatomy 0.000 description 7
- 210000004881 tumor cell Anatomy 0.000 description 7
- 239000003981 vehicle Substances 0.000 description 7
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- 201000004681 Psoriasis Diseases 0.000 description 6
- 229920002472 Starch Polymers 0.000 description 6
- 238000013019 agitation Methods 0.000 description 6
- 229940041181 antineoplastic drug Drugs 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 230000008878 coupling Effects 0.000 description 6
- 238000010168 coupling process Methods 0.000 description 6
- 238000005859 coupling reaction Methods 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 230000018109 developmental process Effects 0.000 description 6
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 230000007246 mechanism Effects 0.000 description 6
- 230000001404 mediated effect Effects 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 239000000825 pharmaceutical preparation Substances 0.000 description 6
- 230000003389 potentiating effect Effects 0.000 description 6
- 206010039073 rheumatoid arthritis Diseases 0.000 description 6
- 239000000741 silica gel Substances 0.000 description 6
- 229910002027 silica gel Inorganic materials 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- 108010039471 Fas Ligand Protein Proteins 0.000 description 5
- 239000012980 RPMI-1640 medium Substances 0.000 description 5
- 102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 description 5
- VEOXVBTXROWDAH-UHFFFAOYSA-N acetic acid;3-[1-(3-aminopropyl)indol-3-yl]-4-(1-methylindol-3-yl)pyrrole-2,5-dione Chemical compound CC(O)=O.C12=CC=CC=C2N(C)C=C1C1=C(C=2C3=CC=CC=C3N(CCCN)C=2)C(=O)NC1=O VEOXVBTXROWDAH-UHFFFAOYSA-N 0.000 description 5
- 230000002137 anti-vascular effect Effects 0.000 description 5
- 230000001640 apoptogenic effect Effects 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- WDOGQTQEKVLZIJ-WAYWQWQTSA-N combretastatin a-4 phosphate Chemical compound C1=C(OP(O)(O)=O)C(OC)=CC=C1\C=C/C1=CC(OC)=C(OC)C(OC)=C1 WDOGQTQEKVLZIJ-WAYWQWQTSA-N 0.000 description 5
- 238000010828 elution Methods 0.000 description 5
- 235000019439 ethyl acetate Nutrition 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 150000002825 nitriles Chemical class 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- 239000012188 paraffin wax Substances 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 238000005160 1H NMR spectroscopy Methods 0.000 description 4
- CPIYLCSBEICGHY-UHFFFAOYSA-N 2-amino-4-(3-bromo-4,5-dimethoxyphenyl)-7-(dimethylamino)-4h-chromene-3-carbonitrile Chemical compound BrC1=C(OC)C(OC)=CC(C2C3=CC=C(C=C3OC(N)=C2C#N)N(C)C)=C1 CPIYLCSBEICGHY-UHFFFAOYSA-N 0.000 description 4
- 235000019489 Almond oil Nutrition 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 4
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 4
- 108010010803 Gelatin Proteins 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 102000004243 Tubulin Human genes 0.000 description 4
- 108090000704 Tubulin Proteins 0.000 description 4
- 239000008168 almond oil Substances 0.000 description 4
- 229910052786 argon Inorganic materials 0.000 description 4
- 210000003719 b-lymphocyte Anatomy 0.000 description 4
- 239000011230 binding agent Substances 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 239000001913 cellulose Substances 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- 229960005527 combretastatin A-4 phosphate Drugs 0.000 description 4
- 229940125904 compound 1 Drugs 0.000 description 4
- 239000012043 crude product Substances 0.000 description 4
- 125000004093 cyano group Chemical group *C#N 0.000 description 4
- 108010011222 cyclo(Arg-Pro) Proteins 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 239000008298 dragée Substances 0.000 description 4
- 238000003818 flash chromatography Methods 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 239000008273 gelatin Substances 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 235000011852 gelatine desserts Nutrition 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 4
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 4
- 125000001624 naphthyl group Chemical group 0.000 description 4
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 4
- ZCCUUQDIBDJBTK-UHFFFAOYSA-N psoralen Chemical compound C1=C2OC(=O)C=CC2=CC2=C1OC=C2 ZCCUUQDIBDJBTK-UHFFFAOYSA-N 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 4
- 239000003381 stabilizer Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 238000005556 structure-activity relationship Methods 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 230000008685 targeting Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 230000000699 topical effect Effects 0.000 description 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 4
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 206010028851 Necrosis Diseases 0.000 description 3
- 102000035195 Peptidases Human genes 0.000 description 3
- 108091005804 Peptidases Proteins 0.000 description 3
- 239000004365 Protease Substances 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 125000004423 acyloxy group Chemical group 0.000 description 3
- 150000001356 alkyl thiols Chemical class 0.000 description 3
- 125000002947 alkylene group Chemical group 0.000 description 3
- 230000001772 anti-angiogenic effect Effects 0.000 description 3
- 230000001093 anti-cancer Effects 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 3
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 3
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 3
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 238000004364 calculation method Methods 0.000 description 3
- 125000004181 carboxyalkyl group Chemical group 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 208000029742 colonic neoplasm Diseases 0.000 description 3
- 238000002648 combination therapy Methods 0.000 description 3
- 239000013068 control sample Substances 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 239000003480 eluent Substances 0.000 description 3
- 239000003623 enhancer Substances 0.000 description 3
- 125000002541 furyl group Chemical group 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000005917 in vivo anti-tumor Effects 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 239000002480 mineral oil Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- VMOWKUTXPNPTEN-UHFFFAOYSA-N n,n-dimethylpropan-2-amine Chemical compound CC(C)N(C)C VMOWKUTXPNPTEN-UHFFFAOYSA-N 0.000 description 3
- 230000017074 necrotic cell death Effects 0.000 description 3
- 230000001613 neoplastic effect Effects 0.000 description 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 229940127084 other anti-cancer agent Drugs 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
- 230000036515 potency Effects 0.000 description 3
- 230000000770 proinflammatory effect Effects 0.000 description 3
- 230000002062 proliferating effect Effects 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 125000004076 pyridyl group Chemical group 0.000 description 3
- 125000006413 ring segment Chemical group 0.000 description 3
- 229960004641 rituximab Drugs 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 125000000547 substituted alkyl group Chemical group 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- 125000001544 thienyl group Chemical group 0.000 description 3
- 150000003573 thiols Chemical class 0.000 description 3
- 210000001685 thyroid gland Anatomy 0.000 description 3
- 150000003626 triacylglycerols Chemical class 0.000 description 3
- 125000001462 1-pyrrolyl group Chemical group [*]N1C([H])=C([H])C([H])=C1[H] 0.000 description 2
- PCAXITAPTVOLGL-UHFFFAOYSA-N 2,3-diaminophenol Chemical compound NC1=CC=CC(O)=C1N PCAXITAPTVOLGL-UHFFFAOYSA-N 0.000 description 2
- NPEMGKLGFVBASX-UHFFFAOYSA-N 2-amino-4-(3-bromo-4,5-dimethoxyphenyl)-4h-chromene-3-carbonitrile Chemical class BrC1=C(OC)C(OC)=CC(C2C3=CC=CC=C3OC(N)=C2C#N)=C1 NPEMGKLGFVBASX-UHFFFAOYSA-N 0.000 description 2
- JMTMSDXUXJISAY-UHFFFAOYSA-N 2H-benzotriazol-4-ol Chemical compound OC1=CC=CC2=C1N=NN2 JMTMSDXUXJISAY-UHFFFAOYSA-N 0.000 description 2
- NOPOGZLNBDUEOW-UHFFFAOYSA-N 3-bromo-4,5-dimethoxybenzaldehyde Chemical compound COC1=CC(C=O)=CC(Br)=C1OC.COC1=CC(C=O)=CC(Br)=C1OC NOPOGZLNBDUEOW-UHFFFAOYSA-N 0.000 description 2
- VXGRJERITKFWPL-UHFFFAOYSA-N 4',5'-Dihydropsoralen Natural products C1=C2OC(=O)C=CC2=CC2=C1OCC2 VXGRJERITKFWPL-UHFFFAOYSA-N 0.000 description 2
- JCIDEANDDNSHQC-UHFFFAOYSA-N 4H-chromene Chemical compound C1=CC=C2CC=COC2=C1 JCIDEANDDNSHQC-UHFFFAOYSA-N 0.000 description 2
- HGFMFKSDOFFKRV-UHFFFAOYSA-N 8h-pyrano[2,3-h]quinoline Chemical class C1=CC=NC2=C(C=CCO3)C3=CC=C21 HGFMFKSDOFFKRV-UHFFFAOYSA-N 0.000 description 2
- FUVASQXCIJNOAE-GDLZYMKVSA-N 9h-fluoren-9-yl n-[2-[[(4r)-2,8-diamino-4-(3-bromo-4,5-dimethoxyphenyl)-3-cyano-4h-chromen-7-yl]amino]-2-oxoethyl]-n-methylcarbamate Chemical compound BrC1=C(OC)C(OC)=CC([C@@H]2C3=CC=C(NC(=O)CN(C)C(=O)OC4C5=CC=CC=C5C5=CC=CC=C54)C(N)=C3OC(N)=C2C#N)=C1 FUVASQXCIJNOAE-GDLZYMKVSA-N 0.000 description 2
- ZZOKVYOCRSMTSS-UHFFFAOYSA-N 9h-fluoren-9-ylmethyl carbamate Chemical compound C1=CC=C2C(COC(=O)N)C3=CC=CC=C3C2=C1 ZZOKVYOCRSMTSS-UHFFFAOYSA-N 0.000 description 2
- RUXVLPDVQNXIAT-YVGXBJCXSA-N 9h-fluoren-9-ylmethyl n-[(2s)-1-[[(4r)-2,8-diamino-4-(3-bromo-4,5-dimethoxyphenyl)-3-cyano-4h-chromen-7-yl]amino]-1-oxopropan-2-yl]carbamate Chemical compound BrC1=C(OC)C(OC)=CC([C@@H]2C3=CC=C(NC(=O)[C@H](C)NC(=O)OCC4C5=CC=CC=C5C5=CC=CC=C54)C(N)=C3OC(N)=C2C#N)=C1 RUXVLPDVQNXIAT-YVGXBJCXSA-N 0.000 description 2
- 229920000856 Amylose Polymers 0.000 description 2
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 2
- 208000000659 Autoimmune lymphoproliferative syndrome Diseases 0.000 description 2
- 102100029761 Cadherin-5 Human genes 0.000 description 2
- 102100035904 Caspase-1 Human genes 0.000 description 2
- 108090000426 Caspase-1 Proteins 0.000 description 2
- 208000011231 Crohn disease Diseases 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- 102000005927 Cysteine Proteases Human genes 0.000 description 2
- 108010005843 Cysteine Proteases Proteins 0.000 description 2
- 208000002249 Diabetes Complications Diseases 0.000 description 2
- 206010012655 Diabetic complications Diseases 0.000 description 2
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- HQMLIDZJXVVKCW-REOHCLBHSA-N L-alaninamide Chemical compound C[C@H](N)C(N)=O HQMLIDZJXVVKCW-REOHCLBHSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 206010062049 Lymphocytic infiltration Diseases 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- 230000018199 S phase Effects 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 108091008605 VEGF receptors Proteins 0.000 description 2
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000000340 anti-metabolite Effects 0.000 description 2
- 230000000118 anti-neoplastic effect Effects 0.000 description 2
- 230000001028 anti-proliverative effect Effects 0.000 description 2
- 229940100197 antimetabolite Drugs 0.000 description 2
- 239000002256 antimetabolite Substances 0.000 description 2
- 238000003782 apoptosis assay Methods 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 108700000707 bcl-2-Associated X Proteins 0.000 description 2
- 102000055102 bcl-2-Associated X Human genes 0.000 description 2
- 235000013871 bee wax Nutrition 0.000 description 2
- 239000012166 beeswax Substances 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000012267 brine Substances 0.000 description 2
- 108010018828 cadherin 5 Proteins 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 101150055276 ced-3 gene Proteins 0.000 description 2
- 230000022131 cell cycle Effects 0.000 description 2
- 238000012054 celltiter-glo Methods 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- QZHPTGXQGDFGEN-UHFFFAOYSA-N chromene Chemical compound C1=CC=C2C=C[CH]OC2=C1 QZHPTGXQGDFGEN-UHFFFAOYSA-N 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 229940097362 cyclodextrins Drugs 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- MBMBGCFOFBJSGT-KUBAVDMBSA-N docosahexaenoic acid Natural products CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 239000010685 fatty oil Substances 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 210000004051 gastric juice Anatomy 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 230000002008 hemorrhagic effect Effects 0.000 description 2
- 230000013632 homeostatic process Effects 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 230000005427 lymphocyte apoptotic process Effects 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- CUONGYYJJVDODC-UHFFFAOYSA-N malononitrile Chemical compound N#CCC#N CUONGYYJJVDODC-UHFFFAOYSA-N 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229960001428 mercaptopurine Drugs 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 230000011278 mitosis Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000035407 negative regulation of cell proliferation Effects 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 description 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 2
- 239000008389 polyethoxylated castor oil Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000005522 programmed cell death Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 235000019419 proteases Nutrition 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000002511 suppository base Substances 0.000 description 2
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 2
- 239000012049 topical pharmaceutical composition Substances 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical class [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- QGVLYPPODPLXMB-UBTYZVCOSA-N (1aR,1bS,4aR,7aS,7bS,8R,9R,9aS)-4a,7b,9,9a-tetrahydroxy-3-(hydroxymethyl)-1,1,6,8-tetramethyl-1,1a,1b,4,4a,7a,7b,8,9,9a-decahydro-5H-cyclopropa[3,4]benzo[1,2-e]azulen-5-one Chemical compound C1=C(CO)C[C@]2(O)C(=O)C(C)=C[C@H]2[C@@]2(O)[C@H](C)[C@@H](O)[C@@]3(O)C(C)(C)[C@H]3[C@@H]21 QGVLYPPODPLXMB-UBTYZVCOSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- QWXZOFZKSQXPDC-NSHDSACASA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)propanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](C)C(O)=O)C3=CC=CC=C3C2=C1 QWXZOFZKSQXPDC-NSHDSACASA-N 0.000 description 1
- DTZFNNJEVHXGIO-XXFAHNHDSA-N (2s)-2-amino-n-[(4r)-2,8-diamino-4-(3-bromo-4,5-dimethoxyphenyl)-3-cyano-4h-chromen-7-yl]propanamide Chemical compound BrC1=C(OC)C(OC)=CC([C@@H]2C3=CC=C(NC(=O)[C@H](C)N)C(N)=C3OC(N)=C2C#N)=C1 DTZFNNJEVHXGIO-XXFAHNHDSA-N 0.000 description 1
- ASWBNKHCZGQVJV-UHFFFAOYSA-N (3-hexadecanoyloxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- NAGAMFAAQBJQOY-UHFFFAOYSA-N 2,7-diamino-4-(3-bromo-4,5-dimethoxyphenyl)-4h-chromene-3-carbonitrile Chemical compound BrC1=C(OC)C(OC)=CC(C2C3=CC=C(N)C=C3OC(N)=C2C#N)=C1 NAGAMFAAQBJQOY-UHFFFAOYSA-N 0.000 description 1
- OBTZDIRUQWFRFZ-UHFFFAOYSA-N 2-(5-methylfuran-2-yl)-n-(4-methylphenyl)quinoline-4-carboxamide Chemical compound O1C(C)=CC=C1C1=CC(C(=O)NC=2C=CC(C)=CC=2)=C(C=CC=C2)C2=N1 OBTZDIRUQWFRFZ-UHFFFAOYSA-N 0.000 description 1
- NDKDFTQNXLHCGO-UHFFFAOYSA-N 2-(9h-fluoren-9-ylmethoxycarbonylamino)acetic acid Chemical compound C1=CC=C2C(COC(=O)NCC(=O)O)C3=CC=CC=C3C2=C1 NDKDFTQNXLHCGO-UHFFFAOYSA-N 0.000 description 1
- IMSODMZESSGVBE-UHFFFAOYSA-N 2-Oxazoline Chemical compound C1CN=CO1 IMSODMZESSGVBE-UHFFFAOYSA-N 0.000 description 1
- ZQNNHAWSCLTIPN-UHFFFAOYSA-N 2-amino-4-(3-bromo-4,5-dimethoxyphenyl)-4,7-dihydropyrano[2,3-e]indole-3-carbonitrile Chemical compound BrC1=C(OC)C(OC)=CC(C2C3=C(C=4C=CNC=4C=C3)OC(N)=C2C#N)=C1 ZQNNHAWSCLTIPN-UHFFFAOYSA-N 0.000 description 1
- ZTKXVRYVYTZMPP-UHFFFAOYSA-N 2-amino-4-(3-bromo-4,5-dimethoxyphenyl)-4,9-dihydropyrano[3,2-g]indole-3-carbonitrile Chemical compound BrC1=C(OC)C(OC)=CC(C2C3=C(C=4NC=CC=4C=C3)OC(N)=C2C#N)=C1 ZTKXVRYVYTZMPP-UHFFFAOYSA-N 0.000 description 1
- UUKJEMKPYMGHDC-UHFFFAOYSA-N 2-amino-7-(dimethylamino)-4-(5-methylpyridin-3-yl)-4h-chromene-3-carbonitrile Chemical compound N#CC1=C(N)OC2=CC(N(C)C)=CC=C2C1C1=CN=CC(C)=C1 UUKJEMKPYMGHDC-UHFFFAOYSA-N 0.000 description 1
- VCJVTEASFNOCBZ-MRXNPFEDSA-N 2-amino-n-[(4r)-2,8-diamino-4-(3-bromo-4,5-dimethoxyphenyl)-3-cyano-4h-chromen-7-yl]acetamide Chemical compound BrC1=C(OC)C(OC)=CC([C@@H]2C3=CC=C(NC(=O)CN)C(N)=C3OC(N)=C2C#N)=C1 VCJVTEASFNOCBZ-MRXNPFEDSA-N 0.000 description 1
- HZLCGUXUOFWCCN-UHFFFAOYSA-N 2-hydroxynonadecane-1,2,3-tricarboxylic acid Chemical compound CCCCCCCCCCCCCCCCC(C(O)=O)C(O)(C(O)=O)CC(O)=O HZLCGUXUOFWCCN-UHFFFAOYSA-N 0.000 description 1
- MGADZUXDNSDTHW-UHFFFAOYSA-N 2H-pyran Chemical compound C1OC=CC=C1 MGADZUXDNSDTHW-UHFFFAOYSA-N 0.000 description 1
- BCHZICNRHXRCHY-UHFFFAOYSA-N 2h-oxazine Chemical compound N1OC=CC=C1 BCHZICNRHXRCHY-UHFFFAOYSA-N 0.000 description 1
- XYVMOLOUBJBNBF-UHFFFAOYSA-N 3h-1,3-oxazol-2-one Chemical compound OC1=NC=CO1 XYVMOLOUBJBNBF-UHFFFAOYSA-N 0.000 description 1
- CLEJZSNZYFJMKD-UHFFFAOYSA-N 3h-1,3-oxazole-2-thione Chemical compound SC1=NC=CO1 CLEJZSNZYFJMKD-UHFFFAOYSA-N 0.000 description 1
- CZWWCTHQXBMHDA-UHFFFAOYSA-N 3h-1,3-thiazol-2-one Chemical compound OC1=NC=CS1 CZWWCTHQXBMHDA-UHFFFAOYSA-N 0.000 description 1
- OCVLSHAVSIYKLI-UHFFFAOYSA-N 3h-1,3-thiazole-2-thione Chemical compound SC1=NC=CS1 OCVLSHAVSIYKLI-UHFFFAOYSA-N 0.000 description 1
- VCMLCMCXCRBSQO-UHFFFAOYSA-N 3h-benzo[f]chromene Chemical compound C1=CC=CC2=C(C=CCO3)C3=CC=C21 VCMLCMCXCRBSQO-UHFFFAOYSA-N 0.000 description 1
- 150000000529 4H-chromenes Chemical class 0.000 description 1
- 229940027041 8-mop Drugs 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 102000004400 Aminopeptidases Human genes 0.000 description 1
- 108090000915 Aminopeptidases Proteins 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 206010003571 Astrocytoma Diseases 0.000 description 1
- 206010051779 Bone marrow toxicity Diseases 0.000 description 1
- 241000244203 Caenorhabditis elegans Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 102100035861 Cytosolic 5'-nucleotidase 1A Human genes 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 102000010911 Enzyme Precursors Human genes 0.000 description 1
- 108010062466 Enzyme Precursors Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000009386 Experimental Arthritis Diseases 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 108010015899 Glycopeptides Proteins 0.000 description 1
- 102000002068 Glycopeptides Human genes 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 101000802744 Homo sapiens Cytosolic 5'-nucleotidase 1A Proteins 0.000 description 1
- 101000611023 Homo sapiens Tumor necrosis factor receptor superfamily member 6 Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 1
- 208000019758 Hypergammaglobulinemia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 208000008771 Lymphadenopathy Diseases 0.000 description 1
- 235000019759 Maize starch Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- QXKHYNVANLEOEG-UHFFFAOYSA-N Methoxsalen Chemical compound C1=CC(=O)OC2=C1C=C1C=COC1=C2OC QXKHYNVANLEOEG-UHFFFAOYSA-N 0.000 description 1
- 102000029749 Microtubule Human genes 0.000 description 1
- 108091022875 Microtubule Proteins 0.000 description 1
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- 239000007990 PIPES buffer Substances 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102100037483 POU domain, class 6, transcription factor 1 Human genes 0.000 description 1
- 101710196406 POU domain, class 6, transcription factor 1 Proteins 0.000 description 1
- 241001111421 Pannus Species 0.000 description 1
- 102000003923 Protein Kinase C Human genes 0.000 description 1
- 108090000315 Protein Kinase C Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 108091027981 Response element Proteins 0.000 description 1
- 102220497176 Small vasohibin-binding protein_T47D_mutation Human genes 0.000 description 1
- 206010041660 Splenomegaly Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 230000033540 T cell apoptotic process Effects 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 102100040403 Tumor necrosis factor receptor superfamily member 6 Human genes 0.000 description 1
- 206010054094 Tumour necrosis Diseases 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 229940122803 Vinca alkaloid Drugs 0.000 description 1
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 1
- HLRAZPBRONOBEX-ZETCQYMHSA-N [(1s)-1-phenylethyl] carbamate Chemical compound NC(=O)O[C@@H](C)C1=CC=CC=C1 HLRAZPBRONOBEX-ZETCQYMHSA-N 0.000 description 1
- SMEGJBVQLJJKKX-HOTMZDKISA-N [(2R,3S,4S,5R,6R)-5-acetyloxy-3,4,6-trihydroxyoxan-2-yl]methyl acetate Chemical compound CC(=O)OC[C@@H]1[C@H]([C@@H]([C@H]([C@@H](O1)O)OC(=O)C)O)O SMEGJBVQLJJKKX-HOTMZDKISA-N 0.000 description 1
- NYRAVIYBIHCEGB-UHFFFAOYSA-N [K].[Ca] Chemical compound [K].[Ca] NYRAVIYBIHCEGB-UHFFFAOYSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 1
- 229940081735 acetylcellulose Drugs 0.000 description 1
- 230000010398 acute inflammatory response Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 229940040563 agaric acid Drugs 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 239000012670 alkaline solution Substances 0.000 description 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000019552 anatomical structure morphogenesis Effects 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 230000002424 anti-apoptotic effect Effects 0.000 description 1
- 229940124650 anti-cancer therapies Drugs 0.000 description 1
- 230000001946 anti-microtubular Effects 0.000 description 1
- 229940044684 anti-microtubule agent Drugs 0.000 description 1
- 230000003356 anti-rheumatic effect Effects 0.000 description 1
- 239000012635 anticancer drug combination Substances 0.000 description 1
- 238000011319 anticancer therapy Methods 0.000 description 1
- 239000003080 antimitotic agent Substances 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000003435 antirheumatic agent Substances 0.000 description 1
- 229940111121 antirheumatic drug quinolines Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- 108700041737 bcl-2 Genes Proteins 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N benzo-alpha-pyrone Natural products C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 1
- 150000001562 benzopyrans Chemical class 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 231100000366 bone marrow toxicity Toxicity 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 101150112018 ced-4 gene Proteins 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 238000004296 chiral HPLC Methods 0.000 description 1
- 230000010428 chromatin condensation Effects 0.000 description 1
- 230000010405 clearance mechanism Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000011281 clinical therapy Methods 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 238000005056 compaction Methods 0.000 description 1
- 238000011254 conventional chemotherapy Methods 0.000 description 1
- 230000000139 costimulatory effect Effects 0.000 description 1
- 235000001671 coumarin Nutrition 0.000 description 1
- 150000004775 coumarins Chemical class 0.000 description 1
- 239000007822 coupling agent Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Natural products NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 238000011393 cytotoxic chemotherapy Methods 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000000254 damaging effect Effects 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 230000002074 deregulated effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- MBMBGCFOFBJSGT-SFGLVEFQSA-N docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C\C\C=C\C\C=C\C\C=C\C\C=C\C\C=C\CCC(O)=O MBMBGCFOFBJSGT-SFGLVEFQSA-N 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 230000008519 endogenous mechanism Effects 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 230000036566 epidermal hyperplasia Effects 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 208000035474 group of disease Diseases 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- 229960001330 hydroxycarbamide Drugs 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 230000003463 hyperproliferative effect Effects 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- PFRDRCIPKPEULG-UHFFFAOYSA-N imidazol-2-imine Chemical compound N=C1N=CC=N1 PFRDRCIPKPEULG-UHFFFAOYSA-N 0.000 description 1
- NBGMRMDAEWWFIR-UHFFFAOYSA-N imidazole-2-thione Chemical compound S=C1N=CC=N1 NBGMRMDAEWWFIR-UHFFFAOYSA-N 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical compound C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 230000008076 immune mechanism Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000016507 interphase Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 239000004922 lacquer Substances 0.000 description 1
- 150000002611 lead compounds Chemical class 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 238000011694 lewis rat Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 208000037841 lung tumor Diseases 0.000 description 1
- 201000000564 macroglobulinemia Diseases 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- FPYJFEHAWHCUMM-UHFFFAOYSA-N maleic anhydride Chemical class O=C1OC(=O)C=C1 FPYJFEHAWHCUMM-UHFFFAOYSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 108010082117 matrigel Proteins 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 231100000682 maximum tolerated dose Toxicity 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000012092 media component Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 210000004688 microtubule Anatomy 0.000 description 1
- 230000008880 microtubule cytoskeleton organization Effects 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- UPSFMJHZUCSEHU-JYGUBCOQSA-N n-[(2s,3r,4r,5s,6r)-2-[(2r,3s,4r,5r,6s)-5-acetamido-4-hydroxy-2-(hydroxymethyl)-6-(4-methyl-2-oxochromen-7-yl)oxyoxan-3-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide Chemical compound CC(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@H](O)[C@@H](NC(C)=O)[C@H](OC=2C=C3OC(=O)C=C(C)C3=CC=2)O[C@@H]1CO UPSFMJHZUCSEHU-JYGUBCOQSA-N 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 210000000633 nuclear envelope Anatomy 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 210000004248 oligodendroglia Anatomy 0.000 description 1
- 229950003600 ombrabulin Drugs 0.000 description 1
- IXWNTLSTOZFSCM-YVACAVLKSA-N ombrabulin Chemical compound C1=C(NC(=O)[C@@H](N)CO)C(OC)=CC=C1\C=C/C1=CC(OC)=C(OC)C(OC)=C1 IXWNTLSTOZFSCM-YVACAVLKSA-N 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000003791 organic solvent mixture Substances 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 150000004880 oxines Chemical class 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 125000005010 perfluoroalkyl group Chemical group 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- QGVLYPPODPLXMB-QXYKVGAMSA-N phorbol Natural products C[C@@H]1[C@@H](O)[C@]2(O)[C@H]([C@H]3C=C(CO)C[C@@]4(O)[C@H](C=C(C)C4=O)[C@@]13O)C2(C)C QGVLYPPODPLXMB-QXYKVGAMSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 230000006461 physiological response Effects 0.000 description 1
- 230000009894 physiological stress Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 230000000861 pro-apoptotic effect Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000003805 procoagulant Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- AGTFZKNBBVSSPY-UHFFFAOYSA-N pyrano[2,3-e]indole Chemical class C1=COC2=C3C=CN=C3C=CC2=C1 AGTFZKNBBVSSPY-UHFFFAOYSA-N 0.000 description 1
- 238000011363 radioimmunotherapy Methods 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 239000011369 resultant mixture Substances 0.000 description 1
- 229940100486 rice starch Drugs 0.000 description 1
- XMVJITFPVVRMHC-UHFFFAOYSA-N roxarsone Chemical group OC1=CC=C([As](O)(O)=O)C=C1[N+]([O-])=O XMVJITFPVVRMHC-UHFFFAOYSA-N 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000012439 solid excipient Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 210000001258 synovial membrane Anatomy 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- CBDKQYKMCICBOF-UHFFFAOYSA-N thiazoline Chemical compound C1CN=CS1 CBDKQYKMCICBOF-UHFFFAOYSA-N 0.000 description 1
- 230000030968 tissue homeostasis Effects 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- 229940078499 tricalcium phosphate Drugs 0.000 description 1
- 235000019731 tricalcium phosphate Nutrition 0.000 description 1
- 229910000391 tricalcium phosphate Inorganic materials 0.000 description 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- XGOYIMQSIKSOBS-UHFFFAOYSA-N vadimezan Chemical compound C1=CC=C2C(=O)C3=CC=C(C)C(C)=C3OC2=C1CC(O)=O XGOYIMQSIKSOBS-UHFFFAOYSA-N 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000006492 vascular dysfunction Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 229940100445 wheat starch Drugs 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyrane Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention is directed to a substituted 4H-chromene represented by the Formula (1R), substantially free from the corresponding (S)-stereoisomer: The present invention also relates to the discovery that compound 1R, substantially free from the corresponding (S)-stereoisomer, is an activator of caspases and inducer of apoptosis, as well as an antivascular agent. Therefore, compound 1R, substantially free from the corresponding (S)-stereoisomer, can be used to induce cell death in a variety of clinical conditions in which uncontrolled growth, and spread of abnormal cells occurs. Compound 1R, substantially free from the corresponding (S)-stereoisomer, also can be used for the treatment of diseases due to overgrowth of vasculature, such as solid tumors and ocular neovascularization.
Description
WO 2008/005572 PCT/US2007/015676 SUBSTITUTED 4-ARYL-CHROMENE AS ACTIVATOR OF CASPASES AND INDUCER OF APOPTOSIS AND AS ANTIVASCULAR AGENT AND THE USE THEREOF BACKGROUND OF THE INVENTION Field of the Invention 10001] This invention is in the field of medicinal chemistry. In particular, the invention relates to the discovery that (R)(-)-2,7,8-triamino-4-(3-bromo-4,5-dimethoxyphenyl)-3 cyano-4H-chromene (iR), substantially free from the corresponding (S)-stereoisomer, is an inducer of apoptosis and is a vascular disrupting agent. The invention also relates to the use of compound IR, substantially free from the corresponding (S)-stereoisomer, as a therapeutically effective anti-cancer agent, and-combination with other anticancer agents, as well as for the treatment of diseases due to overgrowth of vasculature, such as ocular neovascularization. Description of Related Art [0002] Organisms eliminate unwanted cells by a process variously known as regulated cell death, programmed cell death, or apoptosis. Such cell death occurs as a normal aspect of animal development, as well as in tissue homeostasis and aging (Glucksmann, A., Biol. Rev. Cambridge Philos. Soc. 26:59-86 (1951); Glucksmann, A., Archives de Biologie 76:419-437 (1965); Ellis, et al., Dev. 112:591-603 (1991); Vaux, et al., Cell 76:777-779 (1994)). Apoptosis regulates cell number, facilitates morphogenesis, removes harmful or otherwise abnormal cells and eliminates cells that have already performed their function. Additionally, apoptosis occurs in response to various physiological stresses, such as hypoxia or ischemia (W096/20721). [0003] There are a number of morphological changes shared by cells experiencing regulated cell death, including plasma and nuclear membrane blebbing, cell shrinkage (condensation of nucleoplasm and cytoplasm), organelle relocalization and compaction, chromatin condensation and production of apoptotic bodies (membrane enclosed particles containing intracellular material) (Orrenius, S., J. Internal Medicine 237:529-536 (1995)). SUBSTITUTE SHEET (RULE 26) WO 2008/005572 PCT/US2007/015676 2 [0004] Apoptosis is achieved through an endogenous mechanism of cellular suicide (Wyllie, A.H., in Cell Death in Biology and Pathology, Bowen and Lockshin, eds., Chapman and Hall (1981),.pp. 9-34). A cell activates its internally encoded suicide program as a result of either internal or external signals. The suicide program is executed through the activation of a carefully regulated genetic program (Wyllie, et al., Int. Rev. Cyt. 68:251 (1980); Ellis, et al., Ann. Rev. Cell Bio. 7:663 (1991)). Apoptotic cells and bodies are usually recognized and cleared by neighboring cells or macrophages before lysis. Because of this clearance mechanism, inflammation is not induced despite the clearance of great numbers of cells (Orrenius, S., J. Internal Medicine 237:529-536 (1995)). 100051 It has been found that a group of proteases is a key element in apoptosis (see, e.g., Thornberry, Chemistry and Biology 5:R97-R103 (1998); Thornberry, British Med. Bull. 53:478-490 (1996)). Genetic studies in the nematode Caenorhabditis elegans revealed that apoptotic cell death involves at least 14 genes, 2 of which are the pro-apoptotic (death-promoting) ced (for cell death abnormal) genes, ced-3 and ced-4. CED-3 is homologous to interleukin 1 beta-converting enzyme, a cysteine protease, which is now called caspase-1. When these data were ultimately applied to mammals, and upon further extensive investigation, it was found that the mammalian apoptosis system appears to involve a cascade of caspases, or a system that behaves like a cascade of caspases. At present, the caspase family of cysteine proteases comprises 14 different members, and more can be discovered in the future. All known caspases are synthesized as zymogens that require cleavage at an aspartyl residue prior to forming the active enzyme. Thus, caspases are capable of activating other caspases, in the manner of an amplifying cascade. [00061 Apoptosis and caspases are thought to be crucial in the development of cancer (Apoptosis and Cancer Chemotherapy, Hickman and Dive, eds., Humana Press (1999)). There is mounting evidence that cancer cells, while containing caspases, lack parts of the molecular machinery that activates the caspase cascade. This makes the cancer cells lose their capacity to undergo cellular suicide and the cells become immortal - they become cancerous. In the case of the apoptosis process, control points are known to exist that represent points for intervention leading to activation. These control points include the CED-9-BCL-like and CED-3-ICE-like gene family products, which are intrinsic proteins regulating the decision of a cell to survive or die and executing part of the cell death WO 2008/005572 PCT/US2007/015676 3 process itself, respectively (see, Schmitt, et al., Biochem. Cell. Biol. 75:301-314 (1997)). BCL-like proteins include BCL-xL and BAX-alpha, which appear to function upstream of caspase activation. BCL-xL appears to prevent activation of the apoptotic protease cascade, whereas BAX-alpha accelerates activation of the apoptotic protease cascade. [0007] It has been shown that chemotherapeutic (anti-cancer) drugs can trigger cancer cells to undergo suicide by activating the dormant caspase cascade. This can be a crucial aspect of the mode of action of most, if not all, known anticancer drugs (Los, et al., Blood 90:3118-3129 (1997); Friesen, et al., Nat. Med. 2:574 (1996)). The mechanism of action of current antineoplastic drugs frequently involves an attack at specific phases of the cell cycle. In brief, the cell cycle refers to the stages through which cells normally progress during their lifetime. Normally, cells exist in a resting phase termed Go. During multiplication, cells progress to a stage in which DNA synthesis occurs, termed S. Later, cell division, or mitosis occurs, in a phase called M. Antineoplastic drugs, such as cytosine arabinoside, hydroxyurea, 6-mercaptopurine, and methotrexate are S phase specific, whereas antineoplastic drugs, such as vincristine, vinblastine, and paclitaxel are M phase specific. Many slow growing tumors, e.g., colon cancers, exist primarily in the Go phase, whereas rapidly proliferating normal tissues, e.g., bone marrow, exist primarily in the S or M phase. Thus, a drug like 6-mercaptopurine can cause bone marrow toxicity while remaining ineffective for a slow growing tumor. Further aspects of the chemotherapy of neoplastic diseases are known to those skilled in the art (see, e.g., Hardman, et al., eds., Goodman and Gilman's The Pharmacological Basis of Therapeutics, Ninth Edition, McGraw-Hill, New York (1996), pp. 1225-1287). Thus, it is clear that the possibility exists for the activation of the caspase cascade, although the exact mechanisms for doing so are not clear at this point. It is equally clear that insufficient activity of the caspase cascade and consequent apoptotic events are implicated in various types of cancer. The development of caspase cascade activators and inducers of apoptosis is a highly desirable goal in the development of therapeutically effective antineoplastic agents. Moreover, since autoimmune disease and certain degenerative diseases also involve the proliferation of abnormal cells, therapeutic treatment for these diseases could also involve the enhancement of the apoptotic process through the administration of appropriate caspase cascade activators and inducers of apoptosis.
WO 2008/005572 PCT/US2007/015676 4 [0008] It is well known that tumor vasculature is essential for the growth and metastasis of solid tumors. Therefore tumor vasculature is an attractive target for therapy because damaging or blocking a single tumor vessel can kill many tumor cells. There are two major therapeutic approaches targeting tumor vasculature. Antiangiogenic approaches, using antiangiogenic agents such as small molecular inhibitors of VEGF receptors or monoclonal antibody targeting VEGF receptors, are designed to prevent the neovascularization processes in tumors, thus blocking the formation of new blood vessels and tumor growth. Antivascular approaches, using vascular disrupting agents (VDAs, which also were known as vascular targeting agents, VTAs), target the preexisting vessels of tumors, causing vascular shutdown and leading to rapid haemorrhagic necrosis and tumor cell death (Tozer, et al., Nature Review Cancer, 5:423-435 (2005), and Kelland, Current Cancer Therapy Reviews, 1:1-9 (2005)). Vasculature in tumors is known to be proliferating, relatively immature, more permeable and disorganized, in comparison to vasculature in normal tissues. Tumor vascular disrupting agents were designed to exploit these differences between normal and tumor blood vessels and to selectively target tumor vasculature. [00091 Two types of VDAs have been developed. The first types are biological or ligand-directed VDAs which use antibodies, peptides or growth factors to target toxins or pro-coagulants to the tumor endothelium. The second types are small molecule VDAs, and most of them are tubulin-binding agents. Some work through induction of local cytokine production, such as 5,6-dimethylxanthenone-4-acetic acid (DMXAA). VDAs are most effective at killing cells in the poorly perfused hypoxic core of tumors, and leaving a viable rim of well-perfused tumor tissues at the periphery, which can rapidly regrow if not treated. Therefore VDAs as single agents in general have poor anti-tumor effects. However, combination therapies of VDAs with cytotoxic chemotherapy, radiotherapy, and radioimmunotherapy, which target the peripheral tumor cells, have produced excellent responses in many animal tumor models. In general, VDAs are well tolerated and have different side-effect profiles than other types of anticancer therapies. Since VDAs target tumor vasculature, they can kill tumor cells that are resistant to conventional chemotherapy and radiotherapy. In addition, VDAs also should be useful for the treatment of other diseases due to overgrowth of vasculature, such as ocular neovascularization (Numbu, H. et al., Invest Ophthalmol. Vis. Sci. 44: 3650-5 (2003)).
WO 2008/005572 PCT/US2007/015676 5 [00101 Vinca alkaloids and colchicine are known to induce haenorrhagic necrosis of solid tumors. However, these antivascular effects were only observed at doses approaching or exceeding their maximum tolerated doses, therefore they could not be used for therapeutic application. More recently, several tubulin-binding agents interacting at the colchicine-binding site have been found to preferentially target tumor endothelial cells while sparing normal vasculature, and to induce haemorrhagic necrosis of solid tumors at doses that are well tolerated. These compounds include combretastatin A-4 phosphate (CA4P), ZD6126 (N-Acetylcolchinol-O-phosphate) and AVE8062, and have shown high antitumor activity in animal studies, especially in combination with other anticancer agents. Therefore vascular disrupting agents (VDAs) are a promising new class of anti-cancer drugs and several VDAs are currently in clinical trials. [00111 In addition, CA4P was reported recently (Vincent, L. et al., J. Clin. Invest. 115: 2992-3006 (2005)) to induce rapid regression of tumor neovessels through interference with vascular endothelial-cadherin signaling. Specifically, CA4P was found to selectively target endothelial cells, but not smooth muscle cells, and to induce regression of unstable nascent tumor neovessels by rapidly disrupting the molecular engagement of the endothelial cell-specific junctional molecule vascular endothelial cadherin both in vitro and in vivo. These results provided a mechanism for the antiangiogenic effects of CA4P and for its selectivity against nascent tumor neovessels as opposed to normal stabilized vasculature. Therefore, VDAs can also have antiangiogenic effects. [0012] EP537949 discloses derivatives of 4H-naphthol[1,2-b]pyran as antiproliferatives: 2
R
3 :R' ) n 1 0 R 4 wherein, each R' is independently halo, trifluoromethyl, Cia alkoxy, hydroxy, nitro, CIA alkyl, CI4 alkylthio, hydroxy-C 14 alkyl, hydroxy-CI 4 alkoxy, trifluoromethoxy, carboxy, WO 2008/005572 PCT/US2007/015676 6
-COOR
5 where R 5 is an ester group, -CONR 6
R
7 or -NR 6
R
7 where R 6 and R 7 are each hydrogen or C 1
.
4 alkyl;
R
2 is phenyl, naphthyl or heteroaryl selected from thienyl, pyridyl, benzothienyl, quinolinyl, benzofuranyl or benzimidazolyl, wherein said phenyl, naphthyl and heteroaryl groups are optionally substituted, or R 2 is furanyl optionally substituted with C 1 4 alkyl;
R
3 is nitrile, carboxy, -COOR 8 where R 8 is an ester group, -CONR 9
R'
0 where R 9 and R' 0 are each hydrogen or C 2
.
4 alkyl or R"S0 2 where R" is C 14 alkyl or optionally substituted phenyl;
R
4 is -NR 2
R
3 , -NHCOR 2 , -N(COR 2
)
2 or -N=CHOCH 2 R1 2 where R1 2 and R1 3 are each hydrogen or C 14 alkyl optionally substituted with carboxy, or R4 is 0 Il C C I I 0 where X is C 24 alkylene, or R4 is -NHSO 2
R'
4 where R' 4 is C 14 alkyl or optionally substituted phenyl; and n is 0-2. [00131 US5281619 discloses naphthopyrans for therapy of diabetic complications: 2 R3 (R') n I O R 4 wherein, R' is C.
4 alkoxy, OH or COOH;
R
2 is optionally substituted phenyl;
R
3 is nitrile, or R 3 is carboxy or -COOR 8 when R 2 is phenyl substituted with 3-nitro or 3 trifluoromethyl and R8 is an ester group; R4 is NR R' 3 , -NHCOR2, -N(COR 2
)
2 or -N=CHOCH 2 R1 2 , wherein R 2 and R 3 are each H or C 1 4 alkyl; and n is 0-2.
WO 2008/005572 PCT/US2007/015676 7 [00141 EP599514 discloses the preparation of pyranoquinoline derivatives as inhibitors of cell proliferation: R2 0 R 3 P wherein R' is optionally substituted phenyl or optionally substituted heteroaryl selected from thienyl, pyridyl, benzothienyl, quinolinyl, benzofuranyl or benzimidazolyl, or R' is furanyl optionally substituted with CIA alkyl; R2 is nitrile, carboxy, -C0 2
R
4 wherein R 4 is an ester group, -CON(R)R 6 where
R
5 and R 6 are independently H or CI.
4 alkyl, or R 7 S0 2 where R 7 is CI alkyl or optionally substituted phenyl;
R
3 is -NR 8
R
9 , -NHCOR', -N(C0 2
R
8
)
2 , -N=CHOR 8 where R 8 and R 9 are independently H or CI.
4 alkyl, or -NHSO 2
R'
0 where R' 0 is CI 4 alkyl or optionally substituted phenyl, or O 11 C ' C I I where X is C 24 alkylene; and the ring P represents a pyridine fused to the benzopyran nucleus. 100151 EP618206 discloses the preparation of naphthopyran and pyranoquinoline as immunosuppressants and cell proliferation inhibitors: 2 B
R
3 A 0 R 4 (R' ) n- X WO 2008/005572 PCT/US2007/015676 8 wherein, A-B is CH 2
CH
2 or CH=CH; each R' is independently halo, carboxy, trifluoromethyl, hydroxy, CIA alkyl, Ci.4 alkoxy, CIA alkylthio, hydroxy-Ci.
4 alkyl, hydroxy-CI 4 alkoxy, nitrogen-containing heterocyclyl, nitro, trifluoromethoxy, -COOR 5 where R 5 is an ester group, -COR 6 ,
-CONR
6
R
7 or -NR 6
R
7 where R 6 and R 7 are each hydrogen or CI 4 alkyl;
R
2 is phenyl, naphthyl or heteroaryl selected from thienyl, pyridyl, benzothienyl, quinolinyl, benzofuranyl or benzimidazolyl, wherein said phenyl, naphthyl and heteroaryl groups are optionally substituted, or R 2 is furanyl optionally substituted with CIA alkyl;
R
3 is nitrile, carboxy, -COOR 8 where R 8 is an ester group, -CONR 9
R'
0 where R 9 and R' are each hydrogen or C 1
.
4 alkyl, or -SO 2 R" where R 1 is CIA alkyl or optionally substituted phenyl-C 14 alkyl; - R 4 is 1-pyrrolyl, 1-imidazolyl or 1-pyrazolyl, each of which is optionally substituted by one or two C 14 alkyl, carboxyl, hydroxyl-C 14 alkyl or -CHO groups, or R is 1-(1,2,4-triazolyl), 1-(1,3,4-triazolyl) or 2-(1,2,3-triazolyl), each of which is optionally substituted by a CI. alkyl or CI 4 perfluoroalkyl group, or R 4 is 1-tetrazolyl optionally substituted by CI 4 alkyl; X is a pyridine or a benzene ring; and n is 0-2. [00161 EP619314 discloses the preparation of 4-phenyl-4H-naphtho[2,l-b]pyran derivatives: I (R,)n R3
(R
2 )m 0 R4 wherein, Ri and R 2 are independently halo, trifluoromethyl, C 1
-C
4 alkoxy, hydroxy, nitro, Ci-C 4 alkyl, CI-C 4 alkylthio, hydroxy-C-C 4 alkyl, hydroxy-CI-C 4 alkoxy, trifluoromethoxy, carboxy, -COORs where Rg is an ester group, -COR 9 , -CONR 9
R
0 or NRRo 10 where R 9 and Ro are each hydrogen or CI-C 4 alkyl;
R
3 is nitrile, carboxy or -C0 2
R
1 wherein R 1 is an ester group; WO 2008/005572 PCT/US2007/015676 9
R
4 is -NR 12
R
1 3 , -NR 1 2
COR
13 , -N(COR 2 )2 or -N=CHOCH 2
R
2 where R 12 and R 1 3 are each hydrogen or C 1 4 alkyl, or R 4 is 0 11 C
C
II 0 where X is C 2
-C
4 alkylene, or R 4 is optionally substituted 1-pyrrolyl; and m and n are each independently 0-2. 100171 The compounds are said to be useful for the treatment of restenosis, immune disease, and diabetic complications. 100181 Smith, et al., (Bioorg. Med. Chem. Lett. 5:2783-2788 (1995)) reported the anti rheumatic potential of a series of 2,4-di-substituted-4H-naphtho[1,2-b]pyran-3 carbonitriles. They reported that 4-(3-nitrophenyl)-2-(N-succinimido)-4H-naphtho[1,2 b]pyran-3-carbonitrile has proved to be acid stable and still retains biological activity:
NO
2 CN 0 N 0 [00191 Birch, et aL., (Diabetes 45:642-650 (1996)) reported that LY290181, an inhibitor of diabetes-induced vascular dysfunction, blocks protein kinase C-stimulated transcriptional activation through inhibition of transcription factor binding to a phorbol response element: WO 2008/005572 PCT/US2007/015676 10 NO2 CN I I O0 NH 2 LY290181 [0020] Panda, et al., (J. Biol. Chem. 272: 7681-7687 (1997)) reported the suppression of microtubule dynamics by LY290181, which might be the potential mechanism for its antiproliferative action. [00211 Wood, et al., (Mol. Pharmacol. 52: 437-444 (1997)) reported that LY290181 inhibited mitosis and microtubule function through direct tubulin binding. [0022] PCT published patent application W09824427 disclosed antimicrotubule compositions and methods for treating or preventing inflammatory diseases. LY290181 was listed as an antimicrotubule agent. [00231 PCT published patent application WO01/34591 disclosed 4H-chromenes and analogs as activators of caspases and inducers of apoptosis: A Y x z wherein, X is 0, S or NR 6 , wherein R 6 is hydrogen or optionally substituted alkyl; Y is CN, COR 7 , C0 2
R
7 or CONRRy, wherein R 7 , R, and Ry are independently hydrogen, C.I 1 0 alkyl, haloalkyl, aryl, fused aryl, carbocyclic, a heterocyclic group, a heteroaryl group, alkenyl, alkynyl, arylalkyl, arylalkenyl, arylalkynyl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkynyl, carbocycloalkyl, heterocycloalkyl, hydroxyalkyl or aminoalkyl; or R. and Ry are taken together with the nitrogen to which they are attached to form a heterocycle; Z is NR 8
R
9 , NHCOR 8 , N(COR 8
)
2 , N(CORs)(CORg), N=CHOR 8 or N=CHR 8 , wherein R 8 and R 9 are independently H, C.4 alkyl or aryl, or R 8 and R 9 are combined together with the group attached to them to form a heterocycle; WO 2008/005572 PCT/US2007/015676 11
R
5 is hydrogen or C 1
.
0 alkyl; A is optionally substituted and is aryl, heteroaryl, saturated carbocyclic, partially saturated carbocylic, saturated heterocyclic, partially saturated heterocyclic, arylalkyl or heteroarylalkyl; and B is an optionally substituted aromatic or heteroaromatic ring. [00241 PCT published patent application W002/092076 disclosed substituted coumarins and quinolines and analogs as activators of caspases and inducers of apoptosis: A Bj X z wherein, the dashed lines cannot both be a double bond at the same time; X is 0, S or NR 6 , wherein R 6 is hydrogen or optionally substituted alkyl or aryl; Y is CN, COR 7 , C0 2
R
7 or CONR.RY, wherein R 7 , Rx and Ry are independently hydrogen, Cr.
1 0 alkyl, haloalkyl, aryl, fused aryl, carbocyclic, a heterocyclic group, a heteroaryl group, alkenyl, alkynyl, arylalkyl, arylalkenyl, arylalkynyl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkynyl, carbocycloalkyl, heterocycloalkyl, hydroxyalkyl or aminoalkyl; or R, and Ry are taken together with the nitrogen to which they are attached to form a heterocycle; Z is 0, S, halo, NR 8 , or NCORs, wherein R 8 is independently H, CI_4 alkyl or aryl; A is optionally substituted and is aryl, heteroaryl, saturated carbocyclic, partially saturated carbocyclic, saturated heterocyclic, partially saturated heterocyclic, arylalkyl or heteroarylalkyl; and B is optionally substituted and is an aryl, heteroaryl, saturated carbocyclic, partially saturated carbocyclic, saturated heterocyclic, or partially saturated heterocyclic ring. [00251 PCT published patent application W002/092083 disclosed 7,8-fused 4H chromene and analogs as activators of caspases and inducers of apoptosis: WO 2008/005572 PCT/US2007/015676 12 Ri A
R
5 R2 sY B X Z B wherein, X is 0, S or NR 6 , wherein R 6 is hydrogen or optionally substituted alkyl; Y is CN, COR 7 , C0 2
R
7 or CONRRY, wherein R 7 , R, and Ry are independently hydrogen, C.o alkyl, haloalkyl, aryl, fused aryl, carbocyclic, a heterocyclic group, a heteroaryl group, alkenyl, alkynyl, arylalkyl, arylalkenyl, arylalkynyl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkynyl, carbocycloalkyl, heterocycloalkyl, hydroxyalkyl or aminoalkyl; or R, and Ry are taken together with the nitrogen to which they are attached to form a heterocycle; Z is NR 8 R9, NHCORg, N(CORs) 2 , N(CORs)(CORg), N=CHOR 8 or N=CHRs, wherein R 8 and R 9 are independently H, Ci-4 alkyl or aryl, or Rs and R9 are combined together with the group attached to them to form a heterocycle;
RI-R
2 are independently hydrogen, halo, haloalkyl, aryl, fused aryl, carbocyclic, a heterocyclic group, a heteroaryl group, C 1 io alkyl, alkenyl, alkynyl, arylalkyl, arylalkenyl, arylalkynyl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkynyl, carbocycloalkyl, heterocycloalkyl, hydroxyalkyl, aminoalkyl, carboxyalkyl, nitro, amino, cyano, acylamido, hydroxy, thiol, acyloxy, azido, alkoxy, carboxy, methylenedioxy, carbonylamido or alkylthiol;
R
5 is hydrogen or Ca- 10 alkyl; A is optionally substituted and is aryl, heteroaryl, saturated carbocyclic, partially saturated carbocylic, saturated heterocyclic, partially saturated heterocyclic, arylalkyl or heteroarylalkyl; and B is optionally substituted and is a fused thiazole, oxazole, 2-imino-imidazole, 2,1,3-thiadiazo-2-one, thiazol-2-one, oxazol-2-one, imidazol-2-thione, thiazol-2-thione, oxazol-2 -thione, imidazoline, oxazoline, thiazoline, triazole, oxazine, oxazine-2,3-dione, or piperazine ring. 10026] PCT published patent application W002/092594 disclosed substituted 4H chromenes and analogs as activators of caspases and inducers of apoptosis: WO 2008/005572 PCT/US2007/015676 13 R 4 A R3 R I wherein,
RI-R
4 are independently hydrogen, halo, haloalkyl, aryl, fused aryl, carbocyclic, a heterocyclic group, a heteroaryl group, C1.
1 0 alkyl, alkenyl, alkynyl, arylalkyl, arylalkenyl, arylalkynyl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkynyl, carbocycloalkyl, heterocycloalkyl, hydroxyalkyl, aminoalkyl, carboxyalkyl, nitro, amino, cyano, acylamido, hydroxy, thiol, acyloxy, azido, alkoxy, carboxy, methylenedioxy, carbonylamido or alkylthiol; or Ri and R 2 , or R 2 and R 3 , or R3 and R4, taken together with the atoms to which they are attached form an aryl, heteroaryl, partially saturated carbocyclic or partially saturated heterocyclic group, wherein said group is optionally substituted;
R
5 is hydrogen or C 1
.
1 0 alkyl; A is optionally substituted and is aryl, heteroaryl, saturated carbocyclic, partially saturated carbocylic, saturated heterocyclic, partially saturated heterocyclic or arylalkyl; Y is CN, COR 7 , C0 2
R
7 or CONRxRy, wherein R7, R, and Ry are independently hydrogen, C 1
.
1 0 alkyl, haloalkyl, aryl, fused aryl, carbocyclic, a heterocyclic group, a heteroaryl group, alkenyl, alkynyl, arylalkyl, arylalkenyl, arylalkynyl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkynyl, carbocycloalkyl, heterocycloalkyl, hydroxyalkyl or aminoalkyl; or R, and Ry are taken together with the nitrogen to which they are attached to form a heterocycle; and Z is NR 8 Rq, NHCOR 8 , N(CORs) 2 , N(CORs)(COR 9 ), N=CHORs or N=CHRS, wherein R8 and R9 are independently H, C 1
.
4 alkyl or aryl, or R8 and R9 are combined together with the group attached to them to form a heterocycle. [00271 PCT published patent application W003/097806 disclosed substituted 4-aryl-4H pyrrolo[2,3-h]chromenes and analogs as activators of caspases and inducers of apoptosis: WO 2008/005572 PCT/US2007/015676 14
R
4 A RS
R
3 Y I I 0 D wherein, R, is selected from the group consisting of alkyl, cycloalkyl, cycloalkylalkyl, hydroxyalkyl, haloalkyl, alkoxyalkyl, aminoalkyl and oxiranylalkyl;
R
3 and R 4 are independently hydrogen, halo, haloalkyl, aryl, fused aryl, carbocyclic, a heterocyclic group, a heteroaryl group, C 1 .. o alkyl, alkenyl, alkynyl, arylalkyl, arylalkenyl, arylalkynyl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkynyl, carbocycloalkyl, heterocycloalkyl, hydroxyalkyl, aminoalkyl, carboxyalkyl, nitro, amino, cyano, acylamido, hydroxy, thiol, acyloxy, azido, alkoxy, carboxy, methylenedioxy, carbonylamido or alkylthiol;
R
5 is hydrogen or CI.io alkyl; A is optionally substituted and is aryl, heteroaryl, saturated carbocyclic, partially saturated carbocyclic, saturated heterocyclic, partially saturated heterocyclic or arylalkyl; D is optionally substituted and is a heteroaromatic, partially saturated heterocyclic or saturated heterocyclic fused ring, wherein said fused ring has 5 or 6 ring atoms, wherein one or two of said ring atoms are nitrogen atoms and the others of said ring atoms are carbon atoms; Y is CN, COR 19 , C0 2
RI
9 or CONR 2
R
21 , wherein R 1 9 , R 20 and R 2 1 are independently hydrogen, C 10 alkyl, haloalkyl, aryl, fused aryl, carbocyclic, a heterocyclic group, a heteroaryl group, alkenyl, alkynyl, arylalkyl, arylalkenyl, arylalkynyl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkynyl, carbocycloalkyl, heterocycloalkyl, hydroxyalkyl or aminoalkyl; or
R
2 0 and R 2 1 are taken together with the nitrogen to form a heterocycle; and Z is NR 2 2
R
2 3 , NHCOR 22
N(COR
2 3
)
2 , N(COR 22
)(COR
23 ), N=CHOR, or N=CHRig wherein R 2 2 and R 2 3 are independently H, C 1 .4 alkyl or aryl, or R 2 2 and R 2 3 are combined together with the group attached to them to form a heterocycle. [00281 Kasibhatla, et al., (Mol. Cancer Ther. 3:1365-74 (2004)) reported a novel series of 2-amino-4-(3-bromo-4,5-dimethoxy-phenyl)-3-cyano-4H-chromenes as apoptosis- WO 2008/005572 PCT/US2007/015676 15 inducing agents discovered using a cell-based apoptosis screening assay. Several analogues from this series including MX-58151, were found to be tubulin destabilizers with binding site at or close to the colchicine binding site. These compounds displayed high selectivity against proliferating versus resting cells, and were shown to disrupt preformed endothelial cell capillary tubules in vitro, suggesting that they should work as tumor vasculature targeting agents. [00291 Gourdean, et al., (Mol. Cancer Ther. 3:1375-84 (2004)) reported the evaluation of a group of 2-amino-4-(3-bromo-4,5-dimethoxy-phenyl)-3-cyano-4H-chromenes to disrupt tumor vasculature and to induce tumor necrosis in vivo. One of the compounds, named MX-1 16407, was found to be highly active and produced tumor regressions in all testing animals in a human lung tumor xenograft (Calu-6) model. Moreover, MX-116407 significantly enhanced the antitumor activity of cisplatin, resulting in 40% tumor-free animals. [00301 Kemnitzer, et al., (J. Med. Chem. 47:6299-310 (2004)) reported the discovery of 4-aryl-4H-chromenes as a new series of apoptosis inducers and the structure-activity relationships (SAR) of the 4-aryl group. 2-Amino-4-(3-bromo-4,5-dimethoxyphenyl)-3 cyano-7-(dimethylamino)-4H-chromene (MX-58151) and 2-amino-3-cyano-7 (dimethylamino)-4-(5-methyl-3-pyridyl)-4H-chromene were identified as the lead compounds from these studies. OMe MeO Br Me CN CN Me 2 N 0 NH 2 Me 2 N 0 NH 2 MX-58151 [00311 Kemnitzer, et al., (Bioorg. Med. Chem. Lett. 15:4745-51 (2005)) reported the exploration of the SAR of 4-aryl-4H-chromenes via modifications at the 7- and 5-, 6-, 8 positions. Several 7-substituted and 7,8-di-substituted compounds, such as 2,7-diamino 4-(3-bromo-4,5-dimethoxyphenyl)-3-cyano-4H-chromene and 2,7,8-triamino-4-(3- WO 2008/005572 PCT/US2007/015676 16 bromo-4,5-dimethoxyphenyl)-3-cyano-4H-chromene were found to have similar potencies as MX-5815 1, both as caspase activators and inhibitors of cell proliferation. OMe OMe MeO Br MeO Br CN CN l I I
H
2 N O NH2 H 2 N o NH 2
NH
2 [0032] Kemnitzer, et al., (J Med. Chem. 50:2858-2864 (2007)) reported the exploration of the SAR of 4-aryl-4H-chromenes with fused rings at the 7,8-positions. Several of these compounds, such as 2-amino-4-(3-bromo-4,5-dimethoxyphenyl)-3-cyano-4,7 dihydropyrano[2,3-e]indole and 2-amino-4-(3-bromo-4,5-dimethoxyphenyl)-3-cyano-4,9 dihydropyrano[3,2-g]indole were found to be highly active both as caspase activators and inhibitors of cell proliferation. OMe OMe MeO Br MeO Br CN CN HN 0 NH 2 0 NH 2 NH SUMMARY OF THE INVENTION [00331 An embodiment of the present invention relates to the discovery that the R stereoisomer (1R) of 2,7,8-triamino-4-(3-bromo-4,5-dimethoxyphenyl)-3-cyano-4H chromene (1) is an activator of the caspase cascade and inducer of apoptosis, and has antivascular effects and is a vascular disrupting agent (VDA) or vascular targeting agent (VTA). Thus, an embodiment of the present invention relates to the use of compound IR as an inducer of apoptosis and as an antivascular agent.
- 17 [0034] In another embodiment, the present invention relates to a compound of Formula IR, substantially free from the corresponding (S)-stereoisomer, or a pharmaceutically acceptable salt or prodrug thereof. [0035] In another embodiment, the present invention relates to a prodrug of 1R having Formula IL [0036] In another embodiment, the present invention relates to a pharmaceutical composition comprising the compound of Formula 1R, or a pharmaceutically acceptable salt or prodrug thereof, and a pharmaceutically acceptable excipient or carrier [0037] In another embodiment, the present invention relates to a method of treating cancer in an animal suffering therefrom, comprising administering to a mammal in need of such treatment an effective amount of a compound of Formula IR, substantially free from the corresponding (S)-stereoisomer, or a pharmaceutically acceptable salt or prodrug thereof. [0038] [0039] In another embodiment, the present invention relates to a method of treating a disorder responsive to an antivascular agent in an animal suffering therefrom, comprising administering to a mammal in need of such treatment an effective amount of a compound of Formula iR, substantially free from the corresponding (S)-stereoisomer, or a pharmaceutically acceptable salt or prodrug thereof. [0040] In another embodiment, the present invention relates to a method for inhibiting the growth of endothelial cells of an animal in need thereof, comprising delivering to the cells a compound of Formula IR, substantially free from the corresponding (S)-stereoisomer, or a pharmaceutically acceptable salt or prodrug thereof [0041] In another embodiment, the present invention relates to a method for inhibiting vascularization in a tissue of an animal in need thereof comprising delivering to the tissue a compound of Formula 1R, substantially free from the corresponding (S)-stereoisomer, or a pharmaceutically acceptable salt or prodrug thereof, [0042] A method for the separation of an stereoisomer having Formula 1R from the corresponding (S)-stereoisomer is described, comprising contacting a mixture comprising solvent and a racemic mixture comprising 1R and the corresponding (S)-stereoisomer, -18 with a chiral stationary phase, contacting the mixture and the chiral stationary phase with an eluting solvent, and isolating the stereoisomer 1R from the eluting solvent, wherein the stereoisomer IR is isolated substantially free of the corresponding (S)-stereoisomer. [0043] A method of preparing a prodrag of Formula II is described, comprising contacting a compound of Formula IR with a protected amino acid and coupling reagent to form a protected prodrug, and deprotecting the protected prodrug to form the compound of Formula II, wherein the compound of Formula IR is substantially free of the corresponding (S)-stereoisomer. DETAILED DESCRIPTION OF THE INVENTION [0044] "Substantially free" of a given stereoisomer, refers to the stereoisomeric purity of the stereoisomer, and is used herein to mean there is greater than 95% of the given stereoisomer present. For example, in a given composition of stereoisomer 1R that is substantially free of the corresponding (S)-stereoisomer, IS, the (R)-stereoisomer is present in greater than 95%. Stereoisomers can be detected using a variety of techniques, for example, chiral HPLC is used. [0045] The present invention arises out of the surprising discovery that when compound 1, 2,7,8-triamino-4-(3-bromo-4,5-dimethoxyphenyl)-3-cyano-4H-chromene, which is a potent and efficacious activator of the caspase cascade and inducer of apoptosis, and exists as a racemic mixture, was separated into the corresponding R-isomer (-) and S-isomer (+), the R-isomer iR is found to be the active isomer and the S-isomer (+) is found to be essentially inactive. In addition, the R-isomer (-) is found to be an efficacious antivascular agent, OMe oMe OMe McO Br MeO Br MeD Br
AA
CN + H2N 0 NH 2
H
2 N O NH 2
H
2 N C NH 2 N1R( 2 NH1 (+) 3. 3.R (- 35 + WO 2008/005572 PCT/US2007/015676 19 [00461 In an embodiment, the present invention relates to a compound of Formula 1R, substantially free from the corresponding (S)-stereoisomer: OMe MeO Br (IR) CN KI I
H
2 N O NH2
NH
2 or a pharmaceutically acceptable salt or prodrug thereof. In one example, the compound 1R is about 95%, 96%, 97%, 98%, 99% or greater free from the corresponding (S) stereoisomer. In another example, the compound 1R is about 99.9% free from the corresponding (S)-stereoisomer. [00471 Pharmaceutically acceptable addition salts include, but are not limited to, inorganic and organic acid addition salts, such as hydrochloride, hydrobromide, phosphate, sulphate, citrate, lactate, tartrate, maleate, fumarate, mandelate and oxalate. [00481 Prodrugs for use in the present invention include, but are not limited to, amides (e.g., those obtained by condensation with a C 14 0 carboxylic acid, such as 4,7,10,13,16,19-docosahexaenoic acid (DHA), C 3
.
6 dioic acid or anhydride thereof, such as succinic and fumaric anhydrides, amino acids, such as glycine or alanine, according to methods known in the art); imines (e.g., those obtained by condensation with a C 1
.
4 aldehyde or ketone according to methods known in the art); and carbamate, such as those described by Leu, et. al., (J. Med. Chem. 42:3623-3628 (1999)) and Greenwald, et. al., (J. Med. Chem. 42:3657-3667 (1999)). [00491 Amino acids for use in the present invention include natural and non-natural amino acids. Natural amino acids for use in the present invention include alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine and valine. [0050] One specific group of prodrugs are amides prepared using amino acid, especially natural amino acid. Specifically, prodrug of compound 1R having the Formula of II: -20 OMe MeO Br - ( II) N.z CN 2NK ;N0 NH 2 H2H
NH
2 or a pharmaceutically acceptable salt or prodrug thereof, wherein R is hydrogen, alkyl and alkyl substituted with hydroxy, carboxy, carbamoyl, mercapto, imidazolyl, methylthio, aryl, amino or guanidine, or R and the NH2 group that is bonded to the carbon atom to which R is bonded, are taken together to form a ring such as in proline. [0051] Compound 1 can be prepared using any method known in the art, In one example, compound 1 is prepared as illustrated in Scheme 1. Reaction of 2,3-diaminophenol with 5-bromoveratraldehyde (3-bromo-4,5-dimethoxybenzaldehyde) and malononitrile in the presence of a base such as dimethylisopropylamine (DMIPA) in a solvent such as ethanol produced the racemic mixture 1 in yield of 82-90%. Scheme 1 O~e Meo Br Ome Ng + CN Et.H/DMIFA ON NXoH C N I2- 0% 1 [0052] Scheme 2 shows another embodiment of a method for the separation of stereoisomers having Formula 1R or IS from their racemic mixture having Formula 1. In one example, the stereoisomer 1R or IS can be isolated from the eluting solvent substantially free from the other corresponding stereoisomer. In another example, the stereoisomer 1R can be isolated from the eluting solvent about 96, 97, 98, 99 % or greater free from the other corresponding stereoisomer, In another - 21 example, the stereoisomer 1R can be isolated from the eluting solvent about 99% free from the other corresponding stereoisomer. In another example, the stereoisomer 1R can be isolated from the eluting solvent about 99.9% free from the other corresponding stereoisomer. [0053] Scheme 2 shows a method for the separation of a stereoisomer having Formula IR from the corresponding (S)-stereoisomer. The method includes contacting a mixture comprising solvent and a racemic mixture comprising IR and the corresponding (S) stereoisomer with a chiral stationary phase, contacting the mixture and the chiral stationary phase with an eluting solvent, and isolating said stereoisomer 1R from the eluting solvent, wherein the stereoisomer 1R is isolated substantially free of the corresponding (S)-stereoisoner. In another example, the stereoisomer lR is isolated about 99% free from the corresponding (S)-stereoisomer. [0054] The phrase "chiral stationary phase" refers to separation media capable of separating corresponding stereoisomers (enantiomeric compounds). The chiral stationary phase can include chiral molecules and/or polymers bonded to solid supports, chiral phases created in situ on the surface of the solid adsorbent, or surface cavities that allow for specific interactions with one stereoisomer. For example, chiral stationary phases for use in the present invention include, but are not limited to, stationary phases in which chiral proteins, small chiral molecules, polymers of cellulose or amylose, marocyclic glycopeptides or cyclodextrins are coated, bonded or otherwise adsorbed to silica or other solid matrices. Another example of a chiral stationary phase for use in the present invention is an Amylose tris[(S)-a-methylbenzylcarbamate] coated on 20 ym silica gel (available from Daicel Chemical Industries, Ltd. as the CHIRALPAK"AS-V, Tokyo, Japan). [0055] Example solvents for use in the chiral separation include MeOH and acetonitrile. Other solvents can be used, for example, ethyl acetate and ethanol. [0056] In other embodiments, the racemic mixture 1 can also be separated using other methods, including supercritical fluid conditions (SFC) or using simulated moving bed (SMB) technology. (0057] A simulated moving bed apparatus which allows for the separation of iR from a mixture of 1R and IS is commercially available from, for example, NovaSep, Inc., - 22 Boothwyn, PA, or from Knauer, ASI, Franklin, MA (CSEP® Modelh). See, for example, the apparatuses disclosed in U.S. Patent Nos. 3,268,605; 4,434,051 and 5,456,825. See also U.S. Patent Nos. 5,126,055; 5,434,298 and 6,533,936 for methods of purifying stereoisomers using simulated moving bed technology. Scheme 2 O~e OMe OMG MeO Br Br MeG Br cCN +CN 2 r CN ON 0 H 2 N ao NHO 2NN NH, 1R (-) 15 (+) [0058] A method of producing a prodrug of Formula II may include contacting a compound of Formula JR with a protected amino acid and coupling reagent to form a protected prodrug, and deprotecting the protected prodrug to form the compound of Formula II. The compound of Formula IR is substantially free of the corresponding (S) stereoisoner. [0059] Protected amino acids for use in the present invention include protected natural and non-natural amino acids. In one example, the protected amino acid is 9 fluorenylmethyl carbamate protected L-alanine (Fmoc-L-alanine). [0060] Coupling reagents for use in the present invention include those reagents that efficiently, and in high yield, couple amino acids to amino groups. For example, the coupling reagent is a mixture that includes dicyclohexylcarbodiimide (DCC) and hydroxybenzotriazole (HOBt), or in another example, the coupling reagent is a mixture that includes 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide (EDC) and hydroxybenzotriazole (HOBt). It is understood by one ordinary skill in the art that other coupling reagents can be used, [0061] Protected prodrugs can be deprotected using any method that efficiently, and in high yield, cleaves the protecting group from the prodrug, For example, the protected prodrug is deprotected using aqueous base. Examples of base for use in the deprotection includes, but are not limited to, aqueous hydroxide bases, including aqueous solutions of -23 a hydroxide salt. Ilydroxidc salts include, for exaipl, ammonium, sodium, calcium potassium and magnesium hydroxide. [0062] In one embodiment, amino acid prodrugs of compound 1R can be prepared as shown in Scheme 3. Reaction of 1R with a 9-fluorenylmethyl carbamate (Fmoc) protected amino acid, such as Fmoc-L-alanine, in the presence of coupling agents, such as dicyclohexylcarbodiimide (DCC) and hydroxybenzotriazole (HOBt), produced the protected prodrug, Fmoc-alanine amide, of 1R. The Fmoc protecting group can be removed under basic conditions, such as using 2N NaOH, to produce the alanine amide of 1R, which is expected to have better aqueous solubility than that of 1R due to the presence of the more basic amino group. When the aide prodrug is injected into animals, such as mice or human, it is expected that the amino acid will be removed by amino peptidase to produce the active drug 1R. Scheme 3 OMe O~e OMe McQ Br Meo B'r MeO Dr Nmc- 2N NOH Dc. HONt CN ' ;Xt NH2 0 NHHN N 0 N1 [0063] It has been discovered that compound JR is an activator of caspases and inducer of apoptosis. Therefore, compound iR is useful in a variety of clinical conditions in which there is uncontrolled cell growth and spread of abnormal cells, such as in the case of cancer. [0064] Compound iR is a potent and highly efficacious activator of caspases and inducer of apoptosis in drug resistant cancer cells, such as breast and prostate cancer cells, which -24 enables it to kill these drug resistant cancer cells. In comparison, most standard anti cancer drugs are not effective in killing drug resistant cancer cells under the same conditions. Therefore, compound 1R is useful for the treatment of drug resistant cancer in animals. [0065] Another embodiment of the present invention relates to the discovery that compound iR is a potent antivascular agent. Therefore, compound IR is useful for inhibiting the growth of endothelial cells and inhibiting the vascularization of a tissue. In particular, compound 1R is useful for the treatment of cancer in animals via targeting or disrupting vasculature in tumors, blocking blood supply to the tumors and causing tumor cell death. Compound 1R also is expected to be useful for the treatment of other diseases due to overgrowth of vasculature, such as ocular neovascularization. [0066] A therapeutic method useful to modulate in vivo apoptosis or in vivo neoplastic disease is described, comprising administering to a subject in need of such treatment an effective amount of compound IR, substantially free from the corresponding (S) stereoisomer, or a pharmaceutically acceptable salt or prodrug, which functions as a caspase cascade activator and inducer of apoptosis. [0067] Another embodiment of the present invention relates to a therapeutic method comprising administering to an animal an effective amount of compound 1R, substantially free from the corresponding (S)-stereoisomer, or a pharmaceutically acceptable salt or prodrug of said compound, wherein said therapeutic method is useful to treat cancer, which is a group of diseases characterized by the uncontrolled growth and spread of abnormal cells. Such diseases include, but are not limited to, Hodgkin's disease, non-Hodgkin's lymphoma, acute lymphotic leukemia, chronic lymphocytic leukemia, multiple mycloma, neuroblastoma, breast carcinoma, ovarian carcinoma, lung carcinoma, Wilms' tumor, cervical carcinoma, testicular carcinoma, soft-tissue sarcoma, primary macroglobulinemia, bladder carcinoma, chronic granulocytic leukemia, primary brain carcinoma, malignant melanoma, small-cell lung carcinoma, stomach carcinoma, colon carcinoma, malignant pancreatic insulinoma, malignant carcinoid carcinoma, choriocarcinomas, mycosis fungoides, head or neck carcinoma, osteogenic sarcoma, pancreatic carcinoma, acute granulocytic leukemia, hairy cell leukemia, neuroblastoma, WO 2008/005572 PCT/US2007/015676 25 rhabdomyosarcoma, Kaposi's sarcoma, genitourinary carcinoma, thyroid carcinoma, esophageal carcinoma, malignant hypercalcemia, cervical hyperplasia, renal cell carcinoma, endometrial carcinoma, polycythemia vera, essential thrombocytosis, adrenal cortex carcinoma, skin cancer, and prostatic carcinoma. [00681 In practicing the therapeutic methods of the present invention, effective amounts of compositions containing therapeutically effective concentrations of the compound formulated for oral, intravenous, local and topical application, for the treatment of cancer, neoplastic diseases and other diseases in which caspase cascade mediated physiological responses are implicated, are administered to an individual exhibiting the symptoms of one or more of these disorders. The amounts are effective to ameliorate or eliminate one or more symptoms of the disorders. An effective amount of a compound for treating a particular disease is an amount that is sufficient to ameliorate, or in some manner reduce, the symptoms associated with the disease. Such amount can be administered as a single dosage or can be administered according to a regimen, whereby it is effective. The amount can cure the disease but, typically, is administered in order to ameliorate the disease. Typically, repeated administration is required to achieve the desired amelioration of symptoms. [00691 Another embodiment of the present invention relates to a pharmaceutical composition comprising compound IR, or a pharmaceutically acceptable salt or prodrug of said compound, which functions as a caspase cascade activator and inducer of apoptosis in combination with a pharmaceutically acceptable vehicle is provided. In one example, the pharmaceutical composition comprising compound 1R is substantially free of the corresponding (S)-stereoisomer. In another example, the pharmaceutical composition comprising compound 1R is about 95, 96, 97, 98 or 99 % or greater free of the corresponding (S)-stereoisomer. In another example, the pharmaceutical composition comprising compound 1R is about 99.9% free from the corresponding (S)-stereoisomer. [00701 Another embodiment of the present invention relates to a composition effective to treat cancer comprising compound 1R, or a pharmaceutically acceptable salt or prodrug of said compound, which functions as a caspase cascade activator and inducer of apoptosis, in combination with at least one known cancer chemotherapeutic agent, or a pharmaceutically acceptable salt of said agent. Examples of known anti-cancer agents which can be used for combination therapy include, but not are limit to alkylating agents, WO 2008/005572 PCT/US2007/015676 26 such as busulfan, cis-platin, mitomycin C, and carboplatin; antimitotic agents, such as colchicine, vinblastine, paclitaxel, and docetaxel; topo I inhibitors, such as camptothecin and topotecan; topo II inhibitors, such as doxorubicin and etoposide; RNA/DNA antimetabolites such as 5-azacytidine, 5-fluorouracil and methotrexate; DNA antimetabolites, such as 5-fluoro-2'-deoxy-uridine, ara-C, hydroxyurea and thioguanine; and antibodies, such as Herceptin* and Rituxan*. Other known anti-cancer agents which can be used for combination therapy include melphalan, chlorambucil, cyclophosamide, ifosfamide, vincristine, mitoguazone, epirubicin, aclarubicin, bleomycin, mitoxantrone, elliptinium, fludarabine, octreotide, retinoic acid, tamoxifen and alanosine. [00711 Another embodiment of the present invention relates to a composition effective to treat cancer comprising compound 1R, or a pharmaceutically acceptable salt or prodrug of said compound, which functions as a caspase cascade activator, inducer of apoptosis, and as a vascular disrupting agent, in combination with at least one approved cancer therapeutic agent (approved now or in the future), or a pharmaceutically acceptable salt of said agent. These combinations of compound IR with approved cancer therapeutic agents include, as examples, combination with sunitinib, e.g for the treatment of renal cell cancer; combination with sorafenib, e.g. for the treatment of liver cancer; combination with carbotaxel or bevacuzimab, e.g. for the treatment of non-small cell lung cancer; combination with doxorubicin, e.g. for the treatment of ovarian cancer; combination with satraplatin, e.g. for the treatment of prostate cancer; and combination with bevacuzimab, e.g. for the treatment of colorectal cancer. The approved cancer therapeutic can be used at its approved dose and schedule, such as once every 21 days. Compound 1R can be administered, for example, starting the day before, the same day or the day after the approved therapeutic agent. Compound 1R can be administered once a day for 3 consecutive days on a 21 days cycle. Alternative cycles for compound 1R can be, as an example, once a week for 3 weeks on a 28 days cycle. These combination treatments are expected to provide a statistically significant improvement in the reduction of disease progression compared to when the approved cancer therapeutic agent is administered alone. 100721 In practicing the methods of the present invention, the compound of the invention can be administered together with at least one known chemotherapeutic agent as part of a unitary pharmaceutical composition. Alternatively, the compound of the invention can be WO 2008/005572 PCT/US2007/015676 27 administered apart from the at least one known cancer chemotherapeutic agent. In one embodiment, the compound of the invention and the at least one known cancer chemotherapeutic agent are administered substantially simultaneously, i.e. the compounds are administered at the same time or one after the other, so long as the compounds reach therapeutic levels in the blood at the same time. In another embodiment, the compound of the invention and the at least one known cancer chemotherapeutic agent are administered according to their individual dose schedule, so long as the compounds reach therapeutic levels in the blood. [00731 Another embodiment of the present invention relates to a composition effective to treat cancer comprising a bioconjugate of said compound 1R, which functions as a caspase cascade activator and inducer of apoptosis, in bioconjugation with at least one known therapeutically useful antibodies, such as Herceptin* or Rituxan*, growth factors such as DGF, NGF, cytokines, such as IL-2, IL-4, or any molecule that binds to cell surface. The antibodies and other molecules will deliver compound 1R to its targets and make it an effective anticancer agent. The bioconjugates also could enhance the anticancer effect of therapeutically useful antibodies, such as Herceptin* or Rituxan*. [0074] Another embodiment of the present invention relates to a composition effective to treat cancer comprising compound 1R or a pharmaceutically acceptable salt or prodrug of said compound, which functions as a caspase cascade activator and inducer of apoptosis, in combination with radiation therapy. In this embodiment, the compound of the invention can be administered at the same time as the radiation therapy is administered or at a different time. [00751 Another embodiment of the present invention relates to a composition effective for post-surgical treatment of cancer, comprising compound 1R, or a pharmaceutically acceptable salt or prodrug of said compound, which functions as a caspase cascade activator and inducer of apoptosis. The invention also relates to a method of treating cancer by surgically removing the cancer and then treating the animal with one of the pharmaceutical compositions described herein. [0076] A wide range of immune mechanisms operate rapidly following exposure to an infectious agent. Depending on the type of infection, rapid clonal expansion of the T and B lymphocytes occurs to combat the infection. The elimination of the effector cells following an infection is one of the major mechanisms maintaining immune homeostasis.
WO 2008/005572 PCT/US2007/015676 28 This deletion of reactive cells has been shown to be regulated by a phenomenon known as apoptosis. Autoimmune diseases have been identified as a consequence of deregulated cell death. In certain autoimmune diseases, the immune system directs its powerful cytotoxic effector mechanisms against specialized cells, such as oligodendrocytes in multiple sclerosis, the beta cells of the pancreas in diabetes mellitus, and thyrocytes in Hashimoto's thyroiditis (Ohsako, S. & Elkon, K.B., Cell Death Differ. 6:13-21 (1999)). Mutations of the gene encoding the lymphocyte apoptosis receptor Fas/APO-l/CD95 are reported to. be associated with defective lymphocyte apoptosis and autoimmune lymphoproliferative syndrome (ALPS), which is characterized by chronic, histologically benign splenomegaly and generalized lymphadenopathy, hypergammaglobulinemia, and autoantibody formation. (Infante, A.J., et al., J. Pediatr. 133:629-633 (1998) and Vaishnaw, A.K., et al., J Clin. Invest. 103:355-363 (1999)). It was reported that overexpression of Bcl-2, which is a member of the Bcl-2 gene family of programmed cell death regulators with anti-apoptotic activity, in developing B cells of transgenic mice, in the presence of T cell dependent costimulatory signals, results in the generation of a modified B cell repertoire and in the production of pathogenic autoantibodies (Lopez Hoyos, M., et al., Int. J. Mol. Med. 1:475-483 (1998)). It is therefore evident that many types of autoimmune disease are caused by defects of the apoptotic process, and one treatment strategy would be to turn on apoptosis in the lymphocytes that are causing autoimmune disease (O'Reilly, L.A. & Strasser, A., Inflamm. Res. 48:5-21 (1999)). [00771 Fas-Fas ligand (FasL) interaction is known to be required for the maintenance of immune homeostasis. Experimental autoimmune thyroiditis (EAT), characterized by autoreactive T and B cell responses and a marked lymphocytic infiltration of the thyroid, is a good model to study the therapeutic effects of FasL. Batteux, F., et al., (J. Immunol. 162:603-608 (1999)) reported that by direct injection of DNA expression vectors encoding FasL into the inflamed thyroid, the development of lymphocytic infiltration of the thyroid was inhibited and induction of infiltrating T cells death was observed. These results show that FasL expression on thyrocytes can have a curative effect on ongoing EAT by inducing death of pathogenic autoreactive infiltrating T lymphocytes. [00781 Bisindolylmaleimide VIII is known to potentiate Fas-mediated apoptosis in human astrocytoma 1321N1 cells and in Molt-4T cells, both of which were resistant to apoptosis induced by anti-Fas antibody in the absence of bisindolylmaleimide VIII.
WO 2008/005572 PCT/US2007/015676 29 Potentiation of Fas-mediated apoptosis by bisindolylmaleimide VIII was reported to be selective for activated, rather than non-activated, T cells, and was Fas-dependent. Zhou, T., et aL., (Nat. Med. 5:42-48 (1999)) reported that administration of bisindolylmaleimide VIII to rats during autoantigen stimulation prevented the development of symptoms of T cell-mediated autoimmune diseases in two models, the Lewis rat model of experimental allergic encephalitis and the Lewis adjuvant arthritis model. Therefore, the application of a Fas-dependent apoptosis enhancer, such as bisindolylmaleimide VIII, can be therapeutically useful for the more effective elimination of detrimental cells and inhibition of T cell-mediated autoimmune diseases. Therefore, an effective amount of compound 1R, or a pharmaceutically acceptable salt or prodrug of compound 1R, which functions as a caspase cascade activator and inducer of apoptosis, is an effective treatment for autoimmune disease. [00791 Psoriasis is a chronic skin disease that is characterized by scaly red patches. Psoralen plus ultraviolet A (PUVA) is a widely used and effective treatment for psoriasis vulgaris and Coven, et aL. (Photodermatol. Photoimmunol. Photomed. 15:22-27 (1999)) reported that lymphocytes treated with psoralen 8-MOP or TMP plus UVA displayed DNA degradation patterns typical of apoptotic cell death. Ozawa, et aL. (J. Exp. Med. 189:711-718 (1999)) reported that induction of T cell apoptosis could be the main mechanism by which 312-nm UVB resolves psoriasis skin lesions. Low doses of methotrexate can be used to treat psoriasis to restore a clinically normal skin. Heenen, et al. (Arch. Dermatol. Res. 290:240-245 (1998)) reported that low doses of methotrexate can induce apoptosis and this mode of action could explain the reduction in epidermal hyperplasia during treatment of psoriasis with methotrexate. Therefore, an effective amount of compound 1R, or a pharmaceutically acceptable salt or prodrug of compound IR, which functions as a caspase cascade activator and inducer of apoptosis, is an effective treatment for hyperproliferative diseases, such as psoriasis. [00801 Synovial cell hyperplasia is a characteristic of patients with rheumatoid arthritis (RA). Excessive proliferation of RA synovial cells, as well as those defective in synovial cell death, might be responsible for the synovial cell hyperplasia. Wakisaka, et aL. (Clin. Exp. Immunol. 114:119-128 (1998)) found that although RA synovial cells could die via apoptosis through Fas/FasL pathway, apoptosis of synovial cells was inhibited by proinflammatory cytokines present within the synovium, and suggested that inhibition of WO 2008/005572 PCT/US2007/015676 30 apoptosis by the proinflammatory cytokines can contribute to the outgrowth of synovial cells, and lead to pannus formation and the destruction of joints in patients with RA. Therefore, an effective amount of compound 1R, or a pharmaceutically acceptable salt or prodrug of compound 1R, which functions as a caspase cascade activator and inducer of apoptosis, is an effective treatment for rheumatoid arthritis. [00811 Convincing evidence has been accumulating that apoptosis plays a major role in promoting resolution of the acute inflammatory response. Neutrophils are constitutively programmed to undergo apoptosis, thus limiting their pro-inflammatory potential and leading to rapid, specific, and non-phlogistic recognition by macrophages and semi professional phagocytes (Savill, J., J. Leukoc. Biol. 61:375-380 (1997)). Boirivant, et al. (Gastroenterology 116:557-565 (1999)) reported that lamina propria T cells isolated from areas of inflammation in Crohn's disease, ulcerative colitis, and other inflammatory states manifest decreased CD2 pathway-induced apoptosis, and that studies of cells from inflamed Crohn's disease tissue indicate that this defect is accompanied by elevated Bcl-2 levels. Therefore, an effective amount of compound 1R, or a pharmaceutically acceptable salt or prodrug, which functions as a caspase cascade activator and inducer of apoptosis, is an effective treatment for inflammation and inflammatory bowel disease. [00821 Compositions within the scope of the present invention include all compositions wherein compound 1R is contained in an amount that is effective to achieve its intended purpose. While individual needs vary, determination of optimal ranges of effective amounts of each component is within the skill of the art. Typically, the compounds can be administered to mammals, e.g., humans, orally at a dose of 0.0025 to 50 mg/kg, or an equivalent amount of the pharmaceutically acceptable salt thereof, per day, of the body weight of the mammal being treated for apoptosis-mediated disorders. In one example, about 0.01 to about 10 mg/kg is orally administered to treat or prevent such disorders. For intramuscular injection, the dose is generally about one-half of the oral dose. For example, a suitable intramuscular dose would be about 0.0025 to about 25 mg/kg, and another example would be from about 0.01 to about 5 mg/kg. If a known cancer chemotherapeutic agent is also administered, it is administered in an amount which is effective to achieve its intended purpose. The amounts of such known cancer chemotherapeutic agents effective for cancer are well known to those of skill in the art.
WO 2008/005572 PCT/US2007/015676 31 100831 In one example, the unit oral dose comprises about 0.01 to about 50 mg. In another example, the unit oral dose comprises about 0.1 to about 10 mg of the compounds of the present invention. The unit dose can be administered one or more times daily as one or more tablets, each containing from about 0.1 to about 10, conveniently about 0.25 to 50 mg of the compound or its solvates. [0084] In a topical formulation, the compound can be present at a concentration of about 0.01 to 100 mg per gram of carrier. [0085] In addition to administering the compound as a raw chemical, the compounds of the present invention can be administered as part of a pharmaceutical preparation. The pharmaceutical preparation can contain suitable pharmaceutically acceptable carriers that include, for example, excipients and auxiliaries. The excipients and auxiliaries facilitate processing the compounds into preparations which can be used pharmaceutically. [0086] In one example, the orally administered preparations comprise 0.01 to 99 percent, of active compound(s), together with the excipient. In another example, the orally administered preparations comprise about 0.25 to 75 percent of active compound(s), together with the excipient. In further exemplary embodiments, tablets, dragees, or capsules can be used as the forms for orally administering the compounds of the present invention. [00871 In another example, the rectally administered preparations, as well as oral solutions and solutions for injection, comprise about 0.01 to 99 percent of active compound(s), together with the excipient. In another example, these preparations comprise from about 0.25 to 75 percent of active compound(s), together with the excipient. In a further example, suppositories can be used as the form for rectally administering the compounds of the present invention. [0088] The pharmaceutical compositions of the invention can be administered to any animal that can experience the beneficial effects of the compounds of the invention. Foremost among such animals are mammals, e.g., humans and veterinary animals, although the invention is not intended to be so limited. [0089] The pharmaceutical compositions of the present invention can be administered by any means that achieve their intended purpose. For example, administration can be by parenteral, subcutaneous, intravenous, intramuscular, intraperitoneal, transdermal, buccal, intrathecal, intracranial, intranasal or topical routes. Alternatively, or concurrently, WO 2008/005572 PCT/US2007/015676 32 administration can be by the oral route. The dosage administered will be dependent upon the age, health, and weight of the recipient, kind of concurrent treatment, if any, frequency of treatment, and the nature of the effect desired. [00901 The pharmaceutical preparations of the present invention are manufactured in a manner which is itself known, e.g., by means of conventional mixing, granulating, dragee-making, dissolving, or lyophilizing processes. Thus, pharmaceutical preparations for oral use can be obtained by combining the active compounds with solid excipients, optionally grinding the resultant mixture and processing the mixture of granules, after adding suitable auxiliaries, if desired or necessary, to obtain tablets or dragee cores. [00911 Excipients for use in the present invention include, but are not limited to, fillers, such as saccharides, e.g., lactose or sucrose, mannitol or sorbitol; cellulose preparations and/or calcium phosphates, e.g., tricalcium phosphate or calcium hydrogen phosphate; and binders, such as starch paste, using, e.g., maize starch, wheat starch, rice starch, potato starch, gelatin, tragacanth, methyl cellulose, hydroxypropylmethylcellulose, sodium carboxymethylcellulose, and/or polyvinyl pyrrolidone. Optional, disintegrating agents can be added such as the above-mentioned starches and also carboxymethyl-starch, cross-linked polyvinyl pyrrolidone, agar, or alginic acid or a salt thereof, such as sodium alginate. Auxiliaries are, above all, flow-regulating agents and lubricants, e.g., silica, talc, stearic acid or salts thereof, such as magnesium stearate or calcium stearate, and/or polyethylene glycol. Dragee cores are provided with suitable coatings which, optionally, are resistant to gastric juices. For this purpose, concentrated saccharide solutions can be used, which can optionally contain gum arabic, talc, polyvinyl pyrrolidone, polyethylene glycol and/or titanium dioxide, lacquer solutions and suitable organic solvents or solvent mixtures. In order to produce coatings resistant to gastric juices, solutions of suitable cellulose preparations, such as acetylcellulose phthalate or hydroxypropymethyl-cellulose phthalate, are used. Dye stuffs or pigments can be added to the tablets or dragee coatings, e.g., for identification or in order to characterize combinations of active compound doses. [0092] Other pharmaceutical preparations, which can be used orally, include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol. The push-fit capsules can contain the active compounds in the form of granules, which can be mixed with fillers, such as lactose, binders such as starches, and/or lubricants such as talc or magnesium stearate and, optionally, stabilizers.
WO 2008/005572 PCT/US2007/015676 33 In soft capsules, the active compounds are dissolved or suspended in suitable liquids, such as fatty oils, or liquid paraffin. Stabilizers can optionally be added. 100931 Pharmaceutical preparations which can be used rectally include, e.g., suppositories, which consist of a combination of one or more of the active compounds with a suppository base. For example, suitable suppository bases are natural or synthetic triglycerides, or paraffin hydrocarbons. In addition, it is also possible to use gelatin rectal capsules, which consist of a combination of the active compounds with a base. Possible base materials include, e.g., liquid triglycerides, polyethylene glycols, or paraffin hydrocarbons. [00941 Formulations for parenteral administration include aqueous solutions of the active compounds in water-soluble form, e.g., water-soluble salts and alkaline solutions. The active compound can be present in about 0.01 to about 50 mg/mL. In addition, suspensions of the active compounds as appropriate oily injection suspensions can be administered. [0095] Suitable lipophilic solvents, vehicles, excipients or carriers include fatty oils, e.g., sesame oil, or synthetic fatty acid esters, e.g., ethyl oleate or triglycerides; polyethylene glycols ("PEG"), e.g., PEG-200, 400, 600, 800 or 1000; cremophor; cyclodextrins; or block copolymers of poly(ethylene glycol) and poly(propylene glycol) ("poloxamers"), e.g., LUTROL*. In one example, the excipient or carrier is selected from the group consisting of poly(ethylene glycol), block copolymers of poly(ethylene glycol) and poly(propylene glycol), and saline. In another example, a pharmaceutical composition for use in the present invention includes about 10 mg/mL of the compound 1R, substantially free from the corresponding (S)-stereoisomer, about 25% (v/v) poly(ethylene glycol), about 5% (v/v) block copolymers of poly(ethylene glycol) and poly(propylene glycol) and saline. [00961 Aqueous injection suspensions can contain substances, which increase the viscosity of the suspension, e.g., sodium carboxymethyl cellulose, sorbitol, polysorbate, e.g. polysorbate 20, 80, 81, 90 and 94 (e.g., TWEEN*), dextrose, e.g. 1%, 2%, 5%, 10% or 20% solutions of dextrose in water (e.g., 5% dextrose in water "D5W"), and/or dextran. Optionally, the suspension can also contain stabilizers. In one example, the excipient or carrier is selected from the group consisting of poly(ethylene glycol), polysorbate, and a solution of 5% dextrose in water. In another example, a pharmaceutical composition for WO 2008/005572 PCT/US2007/015676 34 use in the present invention includes about 10 mg/mL of the compound 1 R, substantially free from the corresponding (S)-stereoisomer, about 7% (v/v) poly(ethylene glycol) 400, about 9% (v/v) polysorbate 80 and about 84% (v/v) of a solution of 5% dextrose in water. [00971 In accordance with an embodiment of the present invention, compounds of the invention are employed in topical and parenteral formulations and are used for the treatment of skin cancer. [00981 The topical compositions of this invention are formulated as oils, creams, lotions, ointments and the like by choice of appropriate carriers. Suitable carriers include vegetable or mineral oils, white petrolatum (white soft paraffin), branched chain fats or oils, animal fats and high molecular weight alcohol (greater than C 12 ). Particular examples of carriers include those in which the active ingredient is soluble. Emulsifiers, stabilizers, humectants and antioxidants can also be included, as well as agents imparting color or fragrance, if desired. Additionally, transdermal penetration enhancers can be employed in these topical formulations. Examples of such enhancers can be found in U.S. Patent Nos. 3,989,816 and 4,444,762. [00991 In on example, creams are formulated from a mixture of mineral oil, self emulsifying beeswax and water, in which the active ingredient, dissolved in a small amount of an oil, such as almond oil, is admixed. A typical example of such a cream is one which includes about 40 parts water, about 20 parts beeswax, about 40 parts mineral oil and about I part almond oil. [001001 Ointments can be formulated by mixing a solution of the active ingredient in a vegetable oil, such as almond oil with warm soft paraffin, and allowing the mixture to cool. A typical example of such an ointment is one which includes about 30% almond oil and about 70% white soft paraffin by weight. [001011 The following examples are illustrative, but not limiting, of the method and compositions of the present invention. Other suitable modifications and adaptations of the variety of conditions and parameters normally encountered in clinical therapy and which are obvious to those skilled in the art are within the spirit and scope of the invention.
WO 2008/005572 PCT/US2007/015676 35 EXAMPLE 1 Synthesis of 2,7,8-Triamino-4-(3-bromo-4,5-dimethoxy-phenyl)-3-cyano-4H-chromene (1) OMe MeO Br CN H2N 0 NH 2
NH
2 1 1001021 A suspension of 3-bromo-4,5-dimethoxybenzaldehyde (1500 g, 6.12 moles, 1.1 eq) and malononitrile (404 g, 6.12 moles, 1.1 eq) in ethanol 99% (12 L, 7 volumes) was stirred at room temperature under N 2 (g). Dimethylisopropylamine (339 mL, 2.78 moles, 0.5 eq) was added slowly (which caused an exotherm from about 14*C to about 26 *C) and the reaction mixture was stirred at room temperature for about 2 h under N 2 (g). The yellow thick suspension was analyzed by HPLC to monitor the appearance of the Knoevenagel intermediate and the disappearance of the aldehyde. 2,3-Diaminophenol (690.66 g, 5.56 moles, 1 eq) was added and the reaction mixture was stirred at room temperature overnight. The resulting beige-brown suspension was filtered and the cake was washed with cold CH 2 Cl 2 (3000 mL). The solids were dried under vacuum to give 2,7,8-triamino-4-(3-bromo-4,5-dimethoxy-phenyl)-3-cyano-4H-chromene (1.9 kg, 82% . yield). H NMR (300 MHz) (DMSO-d 6 , ppm): 3.71(s, 3H), 3.82 (s, 3H), 4.43 (s, 2H), 4.56 (s, 1H), 4.70 (s, 2H), 6.09 (d, J= 8 Hz, 1H), 6.26 (d, J= 8 Hz, 1H), 6.76 (s, 211), 6.78 (d, J= 2 Hz, 1H), 6.90 (d, J= 2 Hz, 1H).
WO 2008/005572 PCT/US2007/015676 36 EXAMPLE 2 Separation of 2,7,8-Triamino-4-(3-bromo-4,5-dimethoxy-phenyl)-3-cyano-4H-chromene (1) to Produce R(-)-2,7,8-triamino-4-(3-bromo-4,5-dimethoxy-phenyl)-3-yano- 4
H
chromene (1R) by Chiral Preparative HPLC OMe OMe OMe MeO Br MeO Br MeO Br l I N C + CN
H
2 N 0 NH 2
H
2 N H 2 N 0 NH 2
NH
2
NH
2
NH
2 1 IR (-) 1s (+) [00103] A solution of 2,7,8-triamino-4-(3-bromo-4,5-dimethoxy-pheny)-3-cyano- 4
H
chromene (1) in MeOH/CH 3 CN: 95/5 was prepared for injection into a LCI 10 (internal diameter 110 mm) column packed with CHIRALPAK* AS-V 20 p.M silica gel, using a solution of MeOH/CH 3 Ch: 95/5 as eluent, under the following general conditions: General conditions Parameters Set up Temperature of the eluent 30 *C Temperature of the column 30 *C Flow of the eluent About 570 mL/min Flow of feed About 570 ml/min Quantity of feed 230 mL Feed concentration 5.5 g/L Cycle time About 4.25 min Elution sequence Isocratic Fractions F1 (S-isomer) I F2 (R-isomer) [01001 The fractions were collected and combined separately to give compound 1R and 1S. The compounds were analyzed using CHIRALPAK* AS-H 5 pm (150x4.6 mm) analytical column under the following HPLC parameters: WO 2008/005572 PCT/US2007/015676 37 Parameter Condition Mobile Phase A Methanol Flow rate 0.7 mL/min Detection wavelength 254 nm Column temperature 30 *C Autosampler temperature 5 "C Run time 6 min Data collection time 6 min Injection volume 5 pL [01011 Compound 1R and compound 1S were found to have a retention time of 3.19 min and 4.12 min, respectively under these conditions. In addition, compound 1R and compound 1S were found to have optical rotation value CD = -38.460 and aD = +44.620 at 25"C in MeOH, respectively. The absolute configuration of compound 1R was determined by single crystal structure analysis. [0102] HPLC analysis of the racemic mixture 1 showed both stereoisomers were present in about equal proportions. After performing the separation, further HPLC analysis of the isolated stereoisomer IR showed that it was about 99.9% free of the corresponding (S) stereoisomer. EXAMPLE 3 Synthesis of (9H-fluoren-9-yl)methyl (S)-1-((R)-2,8-diamino-3-cyano-4-(3-bromo-4,5 dimethoxyphenyl)-4H-chromen-7-ylcarbamoyl)ethylcarbamate 0rl O ~Br 0 CN Fmoc' N N 0 NH2 = H NH2 [0103] To an oven-dried carousel reaction flask charged with a magnetic stir bar at room temperature under argon was added (R)-2,7,8-triamino-3-cyano-4-(3-bromo-4,5 dimethoxyphenyl)-4H-chromene (0.200 g, 0.479 mmol), Fmoc-Ala-OH (0.179 g, 0.575 mmol), dimethylformamide (2.4 mL), HOBt 0.084 g, 0.62 mmol) and 1-ethyl-3-(3 dimethylaminopropyl)-carbodiimide (EDC) (0.119 g, 0.623 mmol). The black solution WO 2008/005572 PCT/US2007/015676 38 was stirred at room temperature overnight. The solution was diluted with EtOAc (50 mL), washed with water (3 x 30 mL), brine (10 mL), dried over MgSO 4 , filtered and concentrated to give the crude product as a brown residue. Purification by flash column chromatography (silica gel 12 g pre-packed column, gradient elution with EtOAc:Hexanes, 1:9 to 1:4 to 1:1) gave 0.046 g (13%) of the title compound as a yellow solid: mp: 212-217'C (dec); 'H-NMR (DMSO-d): 5 9.37 (br s, 111), 7.89 (d, J= 7.7 Hz, 2H), 7.76-7.69 (m, 3H), 7.44-7.39 (m, 2H), 7.35-7.30 (m, 2H), 6.98 (d, J= 1.9 Hz, IH), 6.88 (br s, 2H), 6.88 (d, J= 8.0 Hz, 111), 6.86 (d, J= 1.9 Hz, 1H), 6.31 (d, J= 8.3 Hz, 1H), 4.79 (br s, 2H), 4.69 (s, 1H), 4.31-4.23 (m, 411), 3.80 (s, 3H), 3.70 (s, 3H), 1.32 (d, J = 6.9 Hz, 3H). EXAMPLE 4 Synthesis of (2S)-2-Amino-N-((R)-2,8-diamino-4-(3-bromo-4,5-dimethoxyphenyl)-3 cyano-4H-chromen-7-yl)propanamide O O Br O CN H2NIAN N 0 NH2 H
NH
2 [01041 To an oven-dried one-neck round bottom reaction flask charged with a magnetic stir bar at room temperature under argon was added (9H-fluoren-9-yl)methyl (S)-1-((R) 2,8-diamino-3-cyano-4-(3-bromo-4,5-dimethoxyphenyl)-4H-chromen-7-ylcarbamoyl) ethylcarbamate (0.045 g, 0.063 mmol), CH 2 Cl 2 :MeOH, 1:1 (2.11 mL) and 2N NaOH (0.063 mL, 0.13 mmol). The orange suspension was stirred at room temperature overnight. The suspension was concentrated leaving a brown residue. The residue was extracted with CHC1 3 (3 x 40 mL), dried over MgSO 4 , filtered and concentrated to give the crude product. Purification by flash column chromatography (silica gel 4g pre-packed column, elution with CH 2 Cl 2 :MeOH, 1:1) gave 0.005 g (16%) of the title compound as a yellow solid: 'H-NMR (DMSO-d 6 ): 5 8.32 (s, 1H), 7.02 (d, J= 8.2 Hz, 1H), 6.98 (d, J= 1.9 Hz, 1H), 6.91 (br s, 2H), 6.86 (d, J= 1.9 Hz, 1H), 6.33 (d, J= 8.5 Hz, 1H), 4.78 (br s, WO 2008/005572 PCT/US2007/015676 39 2H), 4.69 (s, 1H), 3.80 (s, 3H), 3.70 (s, 3H), 1.22 (d, J = 6.9 Hz, 3H). ESI-MS
(C
2 1
H
22 BrN 5
O
4 ) 487.09 m/z (%): 488 [M + H]* (100%), 490 [M + H]j (90%). EXAMPLE 5 Synthesis of (9H-fluoren-9-yl)methyl((R)-2,8-diamino-4-(3-bromo-4,5-dimethoxyphenyl)-3 cyano-4H-chromen-7-ylcarbamoyl)methylcarbamate 0 .O - Br 0 Fmoc N OX NH2 H
NH
2 To an oven-dried carousel reaction flask charged with a magnetic stir bar at rt under argon was added (R)-2,7,8-triamino-3-cyano-4-(3-bromo-4,5-dimethoxyphenyl)-4H-chromene (0.500 g, 1.19 mmol), Fmoc-Gly-OH (0.427 g, 1.44 mmol), dimethylformamide (6.0 mL), HOBt (0.210 g, 1.56 mmol) and EDC (0.299 g, 1.56 mmol). The black solution was stirred at rt overnight. The solution was diluted with EtOAc (100 mL), washed with water (5 x 25 mL), brine (20 mL), dried over MgSO 4 , filtered and concentrated to give the crude product as an orange solid. Purification by flash column chromatography (silica gel 20 g pre-packed column, gradient elution with EtOAc:Hexanes, 1:1 to 2:1) gave 0.125 g (15%) of the title compound as a yellow solid: mp: 128-130'C; 'H-NMR (DMSO-d 6 ): 9.28 (br s, 1H), 7.90 (d, J = 7.1 Hz, 2H), 7.72 (d, J= 7.1 Hz, 2H), 7.62 (in, 1H), 7.42 (t, J= 7.3 Hz, 211), 7.33 (t, J= 7.0 Hz, 2H), 6.99 (s, 1H), 6.92-6.87 (m, 2H), 6.89 (br s, 2H), 6.31 (d, J= 8.2 Hz, 1H), 4.85 (br s, 2H), 4.69 (s, 1H), 4.32-4.25 (in, 3H), 3.84 (in, 2H), 3.80 (s, 3H), 3.70 (s, 3H).
WO 2008/005572 PCT/US2007/015676 40 EXAMPLE 6 2-Amino-N-((R)-2,8-diamino-4-(3-bromo-4,5-dimethoxyphenyl)-3-cyano-4H-chromen-7 yl)acetamide 0 "O Br 0 CN H2N N 0 NH2 H
NH
2 To an oven-dried one-neck round bottom reaction flask charged with a magnetic stir bar at rt under argon was added (9H-fluoren-9-yl)methyl((R)-2,8-diamino-4-(3-bromo-4,5 dimethoxyphenyl)-3-cyano-4H-chromen-7-ylcarbamoyl)methylcarbamate (0.050 g, 0.072 mmol), CH 2
CI
2 :MeOH, 1:1 (2.40 mL) and 2N NaOH (0.072 mL, 0.14 mmol). The orange suspension was stirred at rt overnight. The suspension was concentrated leaving a brown residue. The residue was extracted with CHC1 3 (3 x 40 mL), dried over MgSO 4 , filtered and concentrated to give the crude product. Purification by flash column chromatography (silica gel 4 g pre packed column, gradient elution with CH 2 Cl 2 :MeOH, 96:4 to 90:10 with trace Et 3 N) gave 0.012 g (35%) of the title compound as a yellow solid: 'H-NMR (CDC1 3 ): 9.34 (br s, 11), 6.90 (d, J = 1.9 Hz, 1H), 6.89 (d, J= 8.5 Hz, 1H), 6.71 (d, J= 1.9 Hz, 1H), 6.37 (d, J= 8.2 Hz, 1H), 4.72 (br s, 2H), 4.64 (s, 111), 4.29 (br s, 2H), 3.84 (s, 3H), 3.83 (s, 3H), 3.54 (br s, 211). EXAMPLE 7 Identification of (R)(-)-2,7,8-triamino-4-(3-bromo-4,5-dimethoxy-phenyl)-3-cyano-4H chromene (IR) as a Caspase Cascade Activator and Inducer of Apoptosis in Solid Tumor Cells [01051 Human breast cancer cell lines T-47D and ZR-75-1, human colon cancer cell line DLD-1 and human non-small cell lung cancer cell line H1299 were grown according to media component mixtures designated by American Type Culture Collection + 10% FCS (Invitrogen Corporation), in a 5% CO 2 -95% humidity incubator at 37 "C. T-47D and ZR-75-1 cells were maintained at a cell density between 30 and 80% confluency at a cell WO 2008/005572 PCT/US2007/015676 41 density of 0.1 to 0.6 x 106 cells/mL. Cells were harvested at 600xg and resuspended at 0.65 x 106 cells/mL into appropriate media + 10% FCS. An aliquot of 45 pl of cells was added to a well of a 96-well microtiter plate containing 5 pd of a 10% DMSO in RPMI 1640 media solution containing about 0.16 to 10 pM of 2,7,8-triamino-4-(3-bromo-4,5 dimethoxy-phenyl)-3-cyano-4H-chromene (1) or other test compounds (0.016 to 1 iM final). An aliquot of 45 pl of cells was added to a well of a 96-well microtiter plate containing 5 pl of a 10% DMSO in RPMI-1640 media solution without test compound as the control sample. The samples were mixed by agitation and then incubated at 37 *C for 24 h in a 5% C0 2 -95% humidity incubator. After incubation, the samples were removed from the incubator and 50 pl of a solution containing 20 pM of N-(Ac-DEVD)-N' ethoxycarbonyl-R110 (SEQ ID No:1) fluorogenic substrate (Cytovia, Inc.; US 6,335,429), 20% sucrose (Sigma), 20 mM DTT (Sigma), 200 mM NaCl (Sigma), 40 mM Na PIPES buffer pH 7.2 (Sigma), and 500 ptg/ml lysolecithin (Calbiochem) was added. The samples were mixed by agitation and incubated at room temperature. Using a fluorescent plate reader (Model 1420 Wallac Instruments), an initial reading (T = 0) was made about 1- 2 min after addition of the substrate solution, employing excitation at 485 nm and emission at 530 nm, to determine the background fluorescence of the control sample. After the 3 h incubation, the samples were read for fluorescence as above (T = 3 h). Calculation: 101061 The Relative Fluorescence Unit values (RFU) were used to calculate the sample readings as follows: RFU (T=3h) - Control RFU (T=o) = Net RFU(T=3h) [01071 The activity of caspase cascade activation was determined by the ratio of the net RFU value for 2,7,8-triamino-4-(3-bromo-4,5-dimethoxy-phenyl)-3-cyano-4H-chromene or other test compound to that of control samples. The EC 5 o (nM) was determined by a sigmoidal dose-response calculation (Prism 2.0, GraphPad Software Inc.). The caspase activation potency (EC 5 o) are summarized in Table I: WO 2008/005572 PCT/US2007/015676 42 Table I. Caspase activation potency Structure EC50 (nM) Compound T47D ZR751 DLD-1 H1299 1 OMe 42 35 78 120 MeO Br CN
H
2 N 0 NH 2
NH
2 1R(-) OMe 21 19 57 62 MeO Br CN
H
2 N 0 NH 2
NH
2 R(-) 1S(+) OMe 2489 2006 4571 3206 MeO Br CN
H
2 N O NH 2 ___ ___ __NH 2 S (+) _ _ _ _ _ _ _ __ _ _ _ 3 O 2880 ND ND ND O1 sBr O0 CN Fmoc N 0 NH 2 V
NH
2 4 52 ND ND ND O . Br o CN N 0 NH 2 H
NH
2 WO 2008/005572 PCT/US2007/015676 -43 5 o ~2436 ND ND ND ;x,, Br 0 CN Fmoc >N 01 NH, H NH, _ _ _ _ _ _ _ _ 6 60 ND ND ND
H
2 NJ,. NH, H
NH
2 A 2541 3341 oBr 0 N 0N NH, B 1105503 5778 0 Br NH 0 NH 2
H
2 N _ _ _ __ _ C 160 273 0Br
H
2 N~j 0 NH 2
NH
2 WO 2008/005572 PCT/US2007/015676 44 D 0 B >10000 >10000 Br N ON NH NH, E 3903 5334 0 Br N
H
2 N 0 NH 2 N' H F 4121 5674 0 Br N 0 01 N 0 NH, NH, G o 1421 3750 0 Br oN 0 I-N
H
2 NN0 0 NH2 NH, NH, [01081 Thus, R(-)-2,7,8-triamino-4-(3-bromo-4,5-dimethoxy-phenyl)-3-cyano-4H chromene (1R) is a potent caspase cascade activator and inducer of apoptosis in solid tumor cells, and is the active isomer of the racemate 2,7,8-triamino-4-(3-bromo-4,5 dimethoxy-phenyl)-3-cyano-4H-chromene. S(+)-2,7,8-triamino-4-(3-bromo-4,5 dimethoxy-phenyl)-3-cyano-4H-chromene (1S) is the inactive isomer of the racemate 2,7,8-triamino-4-(3-bromo-4,5-dimethoxy-phenyl)-3-cyano-4H-chromene. The observed activity of 1S might be due to the presence of small percent (-1%) of 1R in the sample tested. Compound 4, the alanine amide prodrug of IR, also is a potent caspase cascade activator and inducer of apoptosis.
WO 2008/005572 PCT/US2007/015676 45 EXAMPLE 8 Identification Of R(-)-2,7,8-triamino-4-(3-bromo-4,5-dimethoxy-phenyl)-3-cyano-4H-chromene (1R) As Antineoplastic Compound That Inhibits Cell Proliferation (Glso) [01091 Human breast cancer cells MX-l and MDAMB435, hepatocarcinoma cells SNU398, colon cancer cells HCTl 16 and HeLa cells were grown and harvested as in Example 7. An aliquot of 90 pL of cells (4.4 x 104 cells/mL) was added to a well of a 96-well microtiter plate containing 5 jiL of a 10 % DMSO in RPMI-1640 media solution containing 10 nM to 100 pM of R(-)-2,7,8-triamino-4-(3-bromo-4,5-dimethoxy-phenyl) 3-cyano-4H-chromene (I nM to 10 pM final). An aliquot of 45 pL of cells was added to a well of a 96-well microtiter plate containing 5 pL of a 10 % DMSO in RPMI-1640 media solution without compound as the control sample for maximal cell proliferation (Lmax). The samples were mixed by agitation and then incubated at 37 *C for 72 h in a 5% CO 2 -95% humidity incubator. After incubation, the samples were removed from the incubator and 25 pL of CellTiter-Glo TM reagent (Promega) was added. The samples -were mixed by agitation and incubated at room temperature for 10-15 min. Plates were then read using a luminescent plate reader (Model SPECTRAfluor Plus, Tecan) to give Ltes values. [01101 Baseline for GI 50 (dose for 50% inhibition of cell proliferation) of initial cell numbers was determined by adding an aliquot of 45 pL of cells or 45 gL of media, respectively, to wells of a 96-well microtiter plate containing 5 JIL of a 10% DMSO in RPMI-1640 media solution. The samples were mixed by agitation and then incubated at 37 *C for 0.5 h in a 5% CO 2 -95% humidity incubator. After incubation, the samples were removed from the incubator and 25 pL of CellTiter-Glo T" reagent (Promega) was added. The samples were mixed by agitation and incubated at 37 *C for 10-15 min at room temperature in a 5% CO 2 -95% humidity incubator. Fluorescence was read as above, (Lstart) defining luminescence for initial cell number used as baseline in G1 50 determinations. Calculation: 101111 GIso (dose for 50% inhibition of cell proliferation) is the concentration where [(LTest - Lstart) / (LMax- Lstart)] = 0.5. [01121 The G1 50 (nM) are summarized in Table II: WO 2008/005572 PCT/US2007/015676 46 Table II. G1 50 in Cancer Cells G1 5 o (nM) Example MX1 Hela MDAMB435 Snu398 HCT116 1R 17 25 9 28 19 [0113] Thus, R(-)-2,7,8-triamino-4-(3-bromo-4,5-dimethoxy-phenyl)-3-cyano-4H chromene is identified as antineoplastic compound that inhibits cell proliferation. EXAMPLE 9 In Vitro Antivascular Activity of R(-)-2,7,8-triamino-4-(3-bromo-4,5-dimethoxy-phenyl) 3-cyano-4H-chromene (1R) in a HUVEC Tube Disruption Assay [0114] Aliquots of Matrigel basement membrane matrix (300 pl, BD Biosciences, Mississauga, Ontario, Canada) were added to each well of 24-well plates (Fisher Scientific Ltd, Nepean, Ontario, Canada) and allowed to incubate for 1 h at 37*C. HUVEC cells (3x 104) were added per well in EGM-2 and incubated for 4 h at 37*C in a 5% CO 2 atmosphere to allow the cells to form tube-like structures. Compound 1R was diluted in DMSO to its respective concentrations, added to cells, and allowed to incubate for 1 h at 37"C in a 5% CO 2 atmosphere. Following the incubation, the medium was gently aspirated and fresh EGM-2 was added and cells were further incubated for 24 h. Miroscopy images were recorded with a Zeiss LSM 510 confocal microscope (Zeiss Canada Ltd, Toronto, Ontario, Canada). The effect of compound IR on capillary tube disruption was evaluated by light microscopy (x40 magnification) and the results are summarized in Table M. Table III. Inhibition of tube formation by compound 1R Tube formation % inhibition Compound # 3.3nM lOnM 30nM 100nM 1R No inhibition 75 100 100 [01151 Thus, (R)(-)-2,7,8-triamino-4-(3-bromo-4,5-dimethoxy-phenyl)-3-cyano-4H chromene (1R) inhibited tube formation at concentration as low as 10 nM, indicating that compound 1R has high antivascular activity.
WO 2008/005572 PCT/US2007/015676 47 EXAMPLE 10 Formulation of R(-)-2,7,8-triamino-4-(3-bromo-4,5-dimethoxy-phenyl)-3-cyano-4H chromene (1R) [0116] Compound IR was prepared as a 10 mg/mL solution with 25% PEG 400(v/v), 5% Lutrol (w/v) in saline. A solution of 6.67% Lutrol in saline was prepared by adding 933 tL of saline into a vial containing 66.7 mg of Lutrol, and mixed until the Lutrol dissolved in the saline. A solution of 40 mg/mL compound 1R in PEG 400 was prepared by adding 973 pL of PEG 400 into a vial containing 40 mg of compound 1R, vortexed and the vial was placed on shaker or rotator until 1R was dissolved in PEG 400. The mixture can be heated occasionally to 50*C to facilitate dissolution if needed. A solution of 10 mg/mL compound 1R in 25% PEG 400 (v/v), 5% Lutrol (w/v) in saline was prepared by pipetting 750 pL of 6.67% Lutrol in saline into a vial containing 250 pL of 40 mg/mL compound 1R in PEG 400, mixing while adding the saline solution. The solution was passed through 0.2 pim filter before injection. 10117] Compound IR also can be formulated as a 10 mg/mL solution in 7% PEG400/ 9% Tween80/ 84% D5W, and used for IV injection. Compound IR also can be formulated as a 10 mg/mL solution in 10% cremophor/ 10% ethanol/ 80% saline, and used for IV injection. EXAMPLE 11 In Vivo Anticancer Activity of (R)(-)-2,7,8-triamino-4-(3-bromo-4,5-dimethoxy-phenyl) 3-cyano-4H-chromene (1R) [0118] MX1 human breast cancer tumors were obtained from the NCI-FCRDC and maintained as tumors in nude mice. Tumor bits were implanted with a trocar into the right mammary area of female nu/nu mice and allowed to grow to an average size of 200 250 mg, about 12 days after being implanted. Animals were randomized and assigned to study groups of 8-10 animals/group. Body weight were determined and tumor size were measured by calipers and converted to volume by the standard formula of Vol=LxW 2 /2. Compound 1R was formulated in 7% PEG400/ 9% Tween80/ 84% D5W and administered IV via the tail vein at the indicated days and doses. Day I of the study was WO 2008/005572 PCT/US2007/015676 48 the first day of treatment. Survival time was the number of days for the tumor to reach 1000 mg or death, whichever occurred earliest. Median survival is the median for the group. Table IV. In vivo antitumor activity of compound 1R in MX-1 model Median survival time (days) Scheme Once a day for Once a day for Once a week, day days 1-5 (QDx5) days 1-3 (QDx3) 1, 8, 15 (QWx3) Vehicle 9.5 7 10 20 mg/kg 46 19 27.5 40 mg/kg >100 38 41 60 mg/kg - 1 78 37.5 [01191 Thus, (R)(-)-2,7,8-triamino-4-(3-bromo-4,5-dimethoxy-phenyl)-3-cyano-4H chromene (1R) increased the median survival time in the MX-1 model compared to vehicle control animals, indicating that compound IR has high in vivo anti-tumor activity as a single agent. EXAMPLE 12 Combination of (R)(-)-2,7,8-triamino-4-(3-bromo-4,5-dimethoxy-phenyl)-3-cyano-4H chromene (1R) with cisplatin and doxorubicin [0120] Mice implanted with MX1 human breast cancer tumors were treated with compound 1R as described in EXAMPLE 11. Cisplatin was administered IP whereas doxorubicin was administered IV at the indicated doses. [0121] Table V. In vivo antitumor activity of compound IR in combination with cisplatin and doxorubicin in MX-1 model Median Number of tumor survival (days) free mice at day 91 Vehicle 8.5 0 of 9 Compound 1R, 40 mg/kg, day 1, 2, 3 (QDx3), 38.5 4 of 9 IV Cisplatin, 2 mg/kg, day 2, IP 11 0 of 9 Compound 1R, 40 mg/kg, day 1, 2, 3 (QDx3), >91 8 of 9 IV, combined with cisplatin, 2 mg/kg, day 2, IP 49 Median Number of tumor survival (days) free mice at day 91 Vehicle 9 0 of7 Compound 1R, 40 mg/kg, day 1, 8. 15 (QWx3), 35 1 of 7 Cisplatin, 2 mg/kg, day 2, 9, 2P 27 1 of 7 Compound IV, 40 mg/kg, day 1, 8, 15 (QWx3), >91 6 of 7 IV;combined with cisplatin, 2 mg/kg, day 2, 9, IP Vehicle 10.5 0 of8 Compound 1R, 40 mg/kg, day 1, 8, 15 (QWx3), 40 1 of 8 IV Doxorubicin, 2 mg/kg, day 2,9, IV 11 0 of9 Compound 1R, 40 mg/kg, day 1, 8, 15 (QWx3), S0.S 4 of 8 IV, combined with doxorubicin, 2 mg/kg, day 2, 9, IV [0122] Thus, combination of (R)(-)-2,7,8-tiamino-4-(3-bro.mo-4,5-dimethoxy-pheny)-3 cyano-4H-chronene (R) with cisplatin or doxorubicin significantly increased the median survival time of mice, and the number of tumor free animals in MX-1 moceI, indicating that compound IR has superior activity when combined with other anticancer agents. [0123] Having now fully described this invention, it will be understood by those of ordinary skill in tbe art that the same can be performed within a wide and equivalent range of conditions, formulations and other parameters without affecting the scope of the invention or any embodiment thereof. All patents, patent applications and publications cited herein are fully incorporated by reference herein in their entirety. Where the terms "comprise", "comprises", "comprised" or "comprising" are used in this specification, they are to be interpreted as specifying the presence of the stated features, integers, steps or components referred to, but not to preclude the presence or addition of one or more other feature, integer, step, component or group thereof. Further, any prior art reference or statement provided in the specification is not to be taken as an admission that such art constitutes, or is to be understood as constituting, part of the common general knowledge in Australia.
Claims (31)
1. A compound of Formula IR, substantially free from the corresponding (S) stereoisomer: OMe MeO Br (1R) CN H2N O NH2 NH 2 or a pharmaceutically acceptable salt or prodrug thereof.
2. The compound of claim 1, wherein compound iR is about 99% or greater free from the corresponding (S)-stereoisomer,
3. The compound of claim 1 or 2, wherein said compound 1R is about 99.9% free from the corresponding (S)-stereoisomer.
4. The compound of any one of claims 1 to 3, wherein said prodrug is an amide obtained by condensation of an amino group on Formula 1R with a C1.o carboxylic acid, anhydride thereof or amino acid; an imine obtained by condensation of an amino group on Formula 1R with a CIA aldehyde or ketone; or a carbamate.
5. The compound of claim 4, wherein said amino acid is selected from the group consisting of alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine and valine.
6. The compound of claim 1, wherein said prodrug has Formula H: - 51 OMe MeO Br CN N O NH R NH2 or a pharmaceutically acceptable salt thereof; wherein R is hydrogen, alkyl and alkyl substituted with hydroxy, carboxy, carbamoyl, mercapto, imidazolyl, methylthio, aryl, amino or guanidine; or R and the NH 2 group that is bonded to the carbon atom to which R is bonded, are taken together to form a ring.
7. A pharmaceutical composition comprising the compound of any one of claims 1 to 6, or a pharmaceutically acceptable salt or prodrug thereof, and a pharmaceutically acceptable excipient or carrier.
8. The pharmaceutical composition of claim 7, comprising about 0.01 to about 50 mg/mL of the compound of any one of claims 1 to 6.
9. The pharmaceutical composition of claim 7 or 8, wherein said excipient or carrier is selected from the group consisting of poly(ethylene glycol), block copolymers of poly(ethylene glycol) and poly(propylene glycol), and saline.
10. The pharmaceutical composition of claim 9, comprising about 10 mg/mL of the compound of any one of claims 1 to 6, about 25% (v/v) poly(ethylene glycol), about 5% (v/v) block copolymers of poly(ethylene glycol) and poly(propylene glycol) and saline.
11. The pharmaceutical composition of claim 7 or 8, wherein said excipient or carrier is selected from the group consisting of polyethylene glycol), polysorbate, and a solution of 5% dextrose in water. - 52
12. The pharmaceutical composition of any one of claims 9 to 11, wherein said poly(ethylene glycol) is PEG 200, 400, 600, 800 or 1000.
13. The pharmaceutical composition of claim 11, wherein said polysorbate is polysorbate 20, 80, 81, 90 or 94.
14. The pharmaceutical composition of claim 13, comprising about 10 mg/mL of the compound of any one of claims 1 to 6, about 7% (v/v) poly(ethylene glycol) 400, about 9 % (v/v) polysorbate 80 and about 84% (v/v) of a solution of 5% dextrose in water.
15. The pharmaceutical composition of any one of claims 7 to 14, further comprising at least one known cancer chemotherapeutic agent, or a pharmaceutically acceptable salt of said agent.
16. A method of treating cancer in an animal suffering therefrom, comprising administering to a mammal in need of such treatment an effective amount of a compound of Formula IR, substantially free from the corresponding (S) stereoisomer: OMe MeO Br (1R) CN N | N H 2 N O NH 2 NH 2 or a pharmaceutically acceptable salt or prodrug thereof.
17. The method of claim 16, wherein said cancer is selected from the group consisting of Hodgkin's disease, non-Hodgkin's lymphoma, acute and chronic lymphocytic leukemias, multiple myeloma, neuroblastoma, breast carcinoma, ovarian carcinoma, lung carcinoma, Wilms' tumor, cervical carcinoma, testicular -53 carcinoma, soft-tissue sarcoma, chronic lymphocytic leukemia, primary macroglobulinenia, bladder carcinoma, chronic granulocytic leukemia, primary brain carcinoma, malignant melanoma, small-cell lung carcinoma, stomach carcinoma, colon carcinoma, malignant pancreatic insulinoma, malignant carcinoid carcinoma, malignant melanoma, choriocarcinoma, mycosis fungoides, head and neck carcinoma, osteogenic sarcoma, pancreatic carcinoma, acute granulocytic leukemia, hairy cell leukemia, neuroblastoma, rhabdomyosarcoma, Kaposi's sarcoma, genitourinary carcinoma, thyroid carcinoma, esophageal carcinoma, malignant hypercalcemia, cervical hyperplasia, renal cell carcinoma, endometrial carcinoma, polycythemia vera, essential thrombocytosis, adrenal cortex carcinoma, skin cancer and prostatic carcinoma.
18. The method of claim 16 or 17, wherein said cancer is a drug resistant cancer.
19. The method of any one of claims 16 to 18, wherein said compound is administered as part of a pharmaceutical composition comprising a pharmaceutically acceptable excipient or carrier.
20. The method of any one of claims 16 to 19, further comprising administering at least one known cancer chemotherapeutic agent, or a pharmaceutically acceptable salt of said agent.
21. The method of claim 20, wherein said known cancer therapeutic agent is selected from the group consisting of busulfan, cis-platin, mitomycin C, carboplatin, colchicine, vinblastine, paclitaxel, docetaxel, camptothecin, topotecan, doxorubicin, etoposide, 5-azacytidine, 5-fluorouracil, methotrexate, 5-fluoro-2' deoxy-uridine, ara-C, hydroxyurea, thioguanine, melphalan, chlorambucil, cyclophosamide, ifosfamide, vincristine, mitoguazone, epirubicin, aclarubicin, bleomycin, mitoxantrone, elliptinium, fludarabine, octreotide, retinoic acid, tarmoxifen, Herceptin*, Rituxanm and alanosine. -54
22. The method of claim 20 or 21, wherein said steps of administering said compound 1R and said known cancer therapeutic agent increases the effectiveness of said known cancer therapeutic agent over its administration alone.
23. The method of any one of claims 16 to 22, further comprising treating said cancer with radiation-therapy.
24. The method of any one of claims 16 to 23, wherein said compound is administered after surgical treatment for cancer.
25. A method of treating a disorder responsive to an antivascular agent in an animal suffering therefrom, comprising administering to a mammal in need of such treatment an effective amount of a compound of Formula iR, substantially free from the corresponding (S)-stereoisomer: OMe MeO Br (lR) CN H 2 N O NH2 NH 2 or a pharmaceutically acceptable salt or prodrug thereof.
26. The method of claim 25, wherein said disorder is selected from cancer, solid tumors, a disease caused by overgrowth of vasculature, or ocular neovascularization.
27. The method of claim 24 or 25, wherein said compound is administered as part of a pharmaceutical composition comprising a pharmaceutically acceptable excipient or carrier.
28. The method of any one of claims 25 to 27, wherein said compound is administered together with a cancer chemotherapeutic agent. - 55
29. The method of claim 28, wherein when: said disorder is renal cell cancer, said cancer chemotherapeutic agent is sunitinib; said disorder is liver cancer, said cancer chemotherapeutic agent is sorafenib; said disorder is non-small cell lung cancer, said cancer chemotherapeutic agent is carbotaxel or bevacuzimab; said disorder is ovarian cancer, said cancer chemotherapeutic agent is doxorubicin; said disorder is prostate cancer, said cancer chemotherapeutic agent is satraplatin; said disorder is colorectal cancer, said cancer chemotherapeutic agent is bevacuzimab.
30. A method for inhibiting the growth of endothelial cells, comprising delivering to the cells a growth inhibitory amount of a compound of any one of claims 1 to 6.
31. A method of inhibiting vascularization in a tissue of an animal in need thereof, comprising delivering to the tissue an anti-vascularization amount of a compound of any one of claims I to 6.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US80667406P | 2006-07-06 | 2006-07-06 | |
US60/806,674 | 2006-07-06 | ||
PCT/US2007/015676 WO2008005572A2 (en) | 2006-07-06 | 2007-07-06 | Substituted 4-aryl-chromene as activator of caspases and inducer of apoptosis and as antivascular agent and the use thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
AU2007271743A1 AU2007271743A1 (en) | 2008-01-10 |
AU2007271743B2 true AU2007271743B2 (en) | 2012-07-26 |
Family
ID=38895260
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2007271743A Ceased AU2007271743B2 (en) | 2006-07-06 | 2007-07-06 | Substituted 4-aryl-chromene as activator of caspases and inducer of apoptosis and as antivascular agent and the use thereof |
Country Status (7)
Country | Link |
---|---|
US (1) | US7968595B2 (en) |
EP (1) | EP2049101A4 (en) |
JP (1) | JP2009542701A (en) |
CN (1) | CN101657196A (en) |
AU (1) | AU2007271743B2 (en) |
CA (2) | CA2938241A1 (en) |
WO (1) | WO2008005572A2 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2447010C (en) * | 2001-05-16 | 2011-08-02 | Cytovia, Inc. | Substituted 4h-chromenes and analogs as activators of caspases and inducers of apoptosis and the use thereof |
ES2379242B1 (en) * | 2010-09-28 | 2013-03-04 | Consejo Superior De Investigaciones Científicas (Csic) | CHROME DERIVATIVES |
US9371333B2 (en) * | 2010-11-12 | 2016-06-21 | Deutsches Krebsforschungszentrum | Chromene derivatives and their analoga as Wnt pathway antagonists |
CN103896899A (en) * | 2012-12-25 | 2014-07-02 | 韩冰 | Compounds for reducing intraocular pressure and preparation method and application thereof |
CN104860915B (en) * | 2015-04-10 | 2016-11-23 | 昆明理工大学 | A kind of preparation method of 4H-4-aryl benzopyrans compounds |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002092594A1 (en) * | 2001-05-16 | 2002-11-21 | Cytovia, Inc. | Substituted 4h-chromenes and analogs as activators of caspases and inducers of apoptosis and the use thereof |
WO2005046575A2 (en) * | 2003-07-29 | 2005-05-26 | Signature R & D Holdings, Lcc | Amino acid prodrugs |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE60008574T2 (en) | 1999-11-05 | 2009-10-01 | Cytovia, Inc., San Diego | Substituted 4H-chromenes and analogues as caspase activators and apoptosis inducers and their use |
EP1392283A4 (en) | 2001-05-16 | 2004-10-20 | Cytovia Inc | Substituted coumarins and quinolines as caspase activators |
US6858607B1 (en) | 2001-05-16 | 2005-02-22 | Cytovia, Inc. | 7,8-fused 4H-chromene and analogs as activators of caspases and inducers of apoptosis and the use thereof |
EP1404329A4 (en) | 2001-06-04 | 2006-11-02 | Cytovia Inc | Substituted 4-aryl-3-(3-aryl-1-oxo-2-propenyl)-2(1h)-quinolinones and analogs as activators of caspases and inducers of apoptosis and the use thereof |
AU2003241482A1 (en) | 2002-05-16 | 2003-12-02 | Cytovia, Inc. | Substituted 4h-chromenes, 2h-chromenes, chromans and analogs as activators of caspases and inducers of apoptosis and the use thereof |
AU2003230411A1 (en) | 2002-05-16 | 2003-12-02 | Cytovia, Inc. | Substituted 4-aryl-4h-pyrrolo(2,3-h)chromenes and analogs as activators of caspases and inducers of apoptosis and the use thereof |
US7135480B2 (en) | 2002-12-12 | 2006-11-14 | Cytovia, Inc. | Substituted 1-benzoyl-3-cyano-pyrrolo [1,2-a] quinolines and analogs as activators of caspases and inducers of apoptosis |
-
2007
- 2007-07-06 CA CA2938241A patent/CA2938241A1/en not_active Abandoned
- 2007-07-06 AU AU2007271743A patent/AU2007271743B2/en not_active Ceased
- 2007-07-06 CN CN200780032539A patent/CN101657196A/en active Pending
- 2007-07-06 WO PCT/US2007/015676 patent/WO2008005572A2/en active Application Filing
- 2007-07-06 US US11/822,535 patent/US7968595B2/en not_active Expired - Fee Related
- 2007-07-06 JP JP2009518401A patent/JP2009542701A/en active Pending
- 2007-07-06 CA CA2656706A patent/CA2656706C/en not_active Expired - Fee Related
- 2007-07-06 EP EP07810283A patent/EP2049101A4/en not_active Ceased
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002092594A1 (en) * | 2001-05-16 | 2002-11-21 | Cytovia, Inc. | Substituted 4h-chromenes and analogs as activators of caspases and inducers of apoptosis and the use thereof |
WO2005046575A2 (en) * | 2003-07-29 | 2005-05-26 | Signature R & D Holdings, Lcc | Amino acid prodrugs |
Non-Patent Citations (3)
Title |
---|
HUTCHINSON L et al: "Antitumor benzothiazoles. 16. Synthesis and pharmaceutical properties of antitumor 2-(4-aminophenyl)benzothiazole amino acid prodrugs" * |
KEMNITZER W et al: "Discovery of 1-17 4-aryl-4H-chromenes as a new series of apoptosis inducers using a cell- and caspase-based high-throughput screening assay. 2. Structureactivity relationships of the 7- and 5-, 6-, 8-positions" * |
MILLER L ET AL: "Preparative Chromatography Resolution of Enantiomers Using Polar Organic Solvents with Polysaccharide Chiral Stationary Phases" * |
Also Published As
Publication number | Publication date |
---|---|
WO2008005572A2 (en) | 2008-01-10 |
JP2009542701A (en) | 2009-12-03 |
EP2049101A2 (en) | 2009-04-22 |
WO2008005572A3 (en) | 2008-03-20 |
US20080085328A1 (en) | 2008-04-10 |
CN101657196A (en) | 2010-02-24 |
US7968595B2 (en) | 2011-06-28 |
AU2007271743A1 (en) | 2008-01-10 |
CA2938241A1 (en) | 2008-01-10 |
EP2049101A4 (en) | 2010-09-15 |
CA2656706C (en) | 2016-09-20 |
CA2656706A1 (en) | 2008-01-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2009200374B2 (en) | Substituted 4H-chromenes and analogs as activators of caspases and inducers of apoptosis and the use thereof | |
US7476741B2 (en) | Substituted 4H-chromens, 2H-chromenes, chromans and analogs as activators of caspases and inducers of apoptosis and the use thereof | |
AU781986B2 (en) | Substituted 4H-chromene and analogs as activators of caspases and inducers of apoptosis and the use thereof | |
US20050090526A1 (en) | Substituted coumarins and quinolines and analogs as activators of caspases and inducers of apoptosis and the use thereof | |
AU2007271743B2 (en) | Substituted 4-aryl-chromene as activator of caspases and inducer of apoptosis and as antivascular agent and the use thereof | |
US6747052B2 (en) | Substituted indole-2-carboxylic acid benzylidene-hydrazides and analogs as activators of caspases and inducers of apoptosis and the use thereof | |
US7622497B2 (en) | Derivatives of gambogic acid and analogs as activators of caspases and inducers of apoptosis | |
Elgaafary et al. | Synthesis of β-enaminonitrile-linked 8-methoxy-1H-benzo [f] chromene moieties and analysis of their antitumor mechanisms | |
US7528164B2 (en) | Substituted 4-aryl-4h-pyrrolo[2,3-h]chromenes and analogs as activators of caspases and inducers of apoptosis and the use thereof | |
Tao et al. | Structurally novel PI3Kδ/γ dual inhibitors characterized by a seven-membered spirocyclic spacer: The SARs investigation and PK evaluation | |
Bae et al. | Antitumor effect of 3-(quinolin-2-ylmethylene)-4, 6-dimethyl-5-hydroxy-7-azaoxindole down-regulating the Gas6-Axl axis | |
EP1392294A1 (en) | 7,8-fused 4$i(h)-chromene and analogs as activators of caspases and inducers of apoptosis and the use thereof | |
EP3468950A1 (en) | Aza-tanshinone derivatives, process for their preparation and their use in therapy | |
JP2008543944A (en) | Benzopyranone compounds for treating cancer | |
AU2002314781A1 (en) | Substituted 4H-chromenes and analogs as activators of caspases and inducers of apoptosis and the use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FGA | Letters patent sealed or granted (standard patent) | ||
MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |